Page last updated: 2024-11-04

nimesulide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It is a member of the sulfonanilide class of drugs and is available in various formulations, including tablets, capsules, and gels. Nimesulide is believed to work by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. It has been shown to be effective in treating a variety of conditions, including osteoarthritis, rheumatoid arthritis, menstrual cramps, and dental pain. Nimesulide is generally well-tolerated, but it can cause side effects, such as gastrointestinal upset, dizziness, and headache. The compound is studied for its efficacy and safety in treating various conditions and for its potential to be developed into new drugs.'

nimesulide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4495
CHEMBL ID56367
CHEBI ID44445
SCHEMBL ID24882
MeSH IDM0059866

Synonyms (198)

Synonym
AC-4524
MLS001148268
HMS3269G17
AB00052332-16
BRD-K76775527-001-06-2
DIVK1C_000693
KBIO1_000693
orthobid
antifloxil
guaxan
nimed
aldoron
nim-03
nisulid
mesulid
nimedex
r-805
nise gel
EU-0100855
flogovital
r 805
methanesulfonamide, n-(4-nitro-2-phenoxyphenyl)-
4'-nitro-2'-phenoxymethansulfonanilid
methanesulfonanilide, 4'-nitro-2'-phenoxy-
sulidene
4-nitro-2-phenoxy-methanesulfonanilide
einecs 257-431-4
nimesulidum [inn-latin]
brn 2421175
nimesulida [inn-spanish]
4-nitro-2-phenoxymethanesulfonanilide
NIM ,
SPECTRUM_001577
IDI1_002137
BCBCMAP01_000034
LOPAC0_000855
51803-78-2
nimesulide
PRESTWICK_618
NCGC00015725-01
lopac-n-1016
BIO2_000382
BIO2_000862
cas-51803-78-2
NCGC00015725-02
BSPBIO_001103
PRESTWICK3_000194
BSPBIO_003112
BSPBIO_000147
PRESTWICK2_000194
aulin
AB00052332
4'-nitro-2'-phenoxymethanesulfonanilide
n-(4-nitro-2-phenoxyphenyl)methanesulfonamide
CHEBI:44445 ,
DB04743
NCGC00021842-06
nimesulide (jan/inn)
D01049
SPECTRUM5_000964
NCGC00021842-05
NCGC00021842-04
NCGC00021842-08
smr000058484
MLS000069680 ,
KBIO2_003011
KBIO3_002612
KBIO2_007193
KBIO2_000443
KBIO2_004625
KBIO3_000825
KBIOSS_000443
KBIO2_002057
KBIO2_005579
KBIOGR_000695
KBIOSS_002057
KBIOGR_000443
KBIO3_000826
SPBIO_002068
PRESTWICK0_000194
SPECTRUM4_000178
SPECTRUM2_001541
SPBIO_001382
PRESTWICK1_000194
SPECTRUM3_001576
NINDS_000693
SPECTRUM1503231
IDI1_000693
BPBIO1_000163
NCGC00021842-03
NCGC00015725-03
NCGC00021842-07
NCGC00015725-06
HMS1990G05
N 1016
HMS2089B14
NCGC00015725-12
CHEMBL56367 ,
nsc-758412
HMS1792G05
HMS502C15
HMS1362G05
STL018679
HMS1922K17
HMS1568H09
bdbm50056999
HMS3262L11
HMS2095H09
R805 ,
dtxsid3037250 ,
tox21_301850
NCGC00255661-01
dtxcid1017250
n-(4-nitro-2-phenoxy-phenyl)methanesulfonamide
A828786
pharmakon1600-01503231
nsc758412
tox21_110207
HMS2234K19
CCG-39319
NCGC00015725-05
NCGC00015725-09
NCGC00015725-10
NCGC00015725-08
NCGC00015725-07
NCGC00015725-13
NCGC00015725-04
NCGC00015725-11
v4tkw1454m ,
nimesulida
nsc 758412
ccris 8225
unii-v4tkw1454m
nimesulide [inn:ban]
nimesulidum
FT-0630650
NCGC00015725-16
LP00855
S2040
AKOS015897356
HMS3371J19
n-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide
gtpl7401
nimesulide [inn]
nimesulide [ep monograph]
nimesulide [jan]
nimesulide [who-dd]
nimesulide [ep impurity]
nimesulide [mart.]
nimesulide [mi]
EI-287
HY-B0363
SCHEMBL24882
NCGC00015725-15
tox21_110207_1
KS-1277
tox21_500855
NCGC00261540-01
W-105866
HMS3403G05
HMS3649A04
N0984
AB00052332_18
AB00052332_17
OPERA_ID_1247
mfcd00079470
sr-01000000218
SR-01000000218-2
HMS3655D13
nimesulide for peak identification, european pharmacopoeia (ep) reference standard
nimesulide, pharmaceutical secondary standard; certified reference material
nimesulide, european pharmacopoeia (ep) reference standard
SR-01000000218-6
SR-01000000218-7
SBI-0050831.P003
HMS3712H09
SW196785-3
HMS3678P07
n-(4-nitro-2-phenoxyphenyl)
nimesulide,(s)
1364966-82-4
SR-01000000218-11
BCP10076
HMS3414P09
Q20994
BRD-K76775527-001-18-7
SDCCGSBI-0050831.P004
HMS3884C22
NCGC00015725-29
D70376
nimesulide 100 microg/ml in acetonitrile
nimesulide for peak identification
BN166246
EN300-7388636
m01ax17
nimesulide (mart.)
nimesulide (ep monograph)
nimesulide (ep impurity)

Research Excerpts

Overview

Nimesulide is a nonsteroidal anti-inflammatory drug and a COX-2 inhibitor with antitumor and antiproliferative activities that induces apoptosis in oral, esophagus, breast, and pancreatic cancer cells. It was discovered in 1971 and firstly commercialized in Italy in 1985.

ExcerptReferenceRelevance
"Nimesulide is a nonsteroidal anti-inflammatory drug and a COX-2 inhibitor with antitumor and antiproliferative activities that induces apoptosis in oral, esophagus, breast, and pancreatic cancer cells. "( Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †.
Been, M; Huber, E; Liao, EE; Lo, CH; Sachs, JN; Thomas, DD; Vunnam, N; Young, MC, 2023
)
3.8
"Nimesulide is a cyclooxygenase-2 inhibitor, which has also been reported to exert a significant antioxidant effect."( Can the negative effects of ketamine abuse on female genital organs be prevented by nimesulide? An experimental study.
Kaplan, S; Mammadov, R; Onat, T; Sunar, M; Turkler, C; Yazici, GN; Yildirim, E, 2019
)
1.46
"Nimesulide is an inhibitor of COX-2 with antioxidant and anti-inflammatory effects. "( Proteomics-based screening of the target proteins associated with antidepressant-like effect and mechanism of nimesulide.
Luo, W; Luo, Y; Yang, J, 2020
)
2.21
"Nimesulide is a non-steroidal anti-inflammatory drug still marketed in many countries. "( Serious liver injury induced by Nimesulide: an international collaborative study.
Alvarez-Alvarez, I; Anders, M; Andrade, RJ; Arrese, M; Bessone, F; Carrilho, F; Colombato, L; Fainboim, H; Fassio, E; Gualano, G; Hernandez, N; Lucena, MI; Medina-Caliz, I; Mendizabal, M; Niu, H; Ono, SK; Parana, R; Peralta, M; Reggiardo, MV; Ridruejo, E; Robles-Diaz, M; Stephens, C; Tanno, F; Tanno, H, 2021
)
2.35
"Nimesulide is an anti-inflammatory drug that is known to exhibit dimorphism; however up to now its stability behavior was not clear, as few thermodynamic data were available."( Pressure-temperature phase diagram of the dimorphism of the anti-inflammatory drug nimesulide.
Barrio, M; Céolin, R; Huguet, J; Rietveld, IB; Robert, B; Tamarit, JL, 2017
)
1.4
"Nimesulide, which is a specific cyclooxygenase-2 inhibitor drug, have antioxidant, antiinflammatory, analgesics and antipyretic effects."( The investigation of the protective effects of nimesulide on experimental testicular ischemia-reperfusion injury in rats.
Altuner, D; Bozkurt, AS; Gulaboglu, M; Keskin Cimen, F; Polat, EC,
)
1.11
"Nimesulide is a relatively selective cyclooxygenase (COX)-2 inhibitor, non-steroidal anti-inflammatory drug; it has been discovered in 1971 and firstly commercialized in Italy in 1985. "( The relatively selective cyclooxygenase-2 inhibitor nimesulide: What's going on?
Caiazzo, E; Cicala, C; Ialenti, A, 2019
)
2.21
"Nimesulide is a nonsteroidal anti-inflammatory drug possessing analgesic and antipyretic properties. "( Nimesulide analogues: From anti-inflammatory to antitumor agents.
Almeida, P; Catarro, M; Ramos, SS; Serrano, JL; Silvestre, S, 2019
)
3.4
"Nimesulide (NIM) is an insoluble nonsteroidal anti-inflammatory drug (NSAID). "( Nimesulide/methyl β-cyclodextrin inclusion complexes: physicochemical characterization, solubility, dissolution, and biological studies.
Auda, SH, 2014
)
3.29
"Nimesulide is a pharmacological agent and selective COX-2 inhibitor. "( Protective effect of nimesulide against hepatic ischemia/reperfusion injury in rats: effects on oxidant/antioxidants, DNA mutation and COX-1/COX-2 levels.
Demiryilmaz, I; Gulapoglu, M; Kisaoglu, A; Suleyman, H; Turan, MI; Yilmaz, I, 2014
)
2.16
"Nimesulide is a selective inhibitor of the enzyme cyclooxygenase 2. "( Nimesulide-induced fatal acute liver failure in an elderly woman with metastatic biliary adenocarcinoma. A case report.
Bernardes, SS; Guembarovski, AF; Kishima, MO; Moreira, EG; Souza-Nogueira, A; Turini, CA; Turini, TL,
)
3.02
"Nimesulide is a COX-2 inhibitor used for symptomatic relief of rheumatoid arthritis. "( Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
Abdel-Naim, AB; Al-Abbasi, FA; Al-Abd, AM; El-Eraky, WI; Khalifa, AE; Nagy, AA; Nofal, SM; Williams, RO, 2014
)
3.29
"Nimesulide (NIM) is a nonsteroidal anti-inflammatory drug, and clinical treatment with NIM has been associated with severe hepatotoxicity. "( Chemical and Enzymatic Transformations of Nimesulide to GSH Conjugates through Reductive and Oxidative Mechanisms.
Chen, X; Pang, X; Xie, C; Zhong, D; Zhou, L, 2015
)
2.12
"Nimesulide is a drug with antioxidant, antiinflammatory and antiulcer features."( Effects of nimesulide on the small intestine mucositis induced by methotrexate in rats.
Altuner, D; Arslan, A; Cetin, N; Cimen, FK; Coban, TA; Kuzucu, M; Nalkiran, HS; Ozcicek, A; Suleyman, B; Suleyman, H, 2016
)
1.55
"Nimesulide (NIM) is a classic nonsteroidal anti-inflammatory drug. "( Nimesulide and 4'-Hydroxynimesulide as Bile Acid Transporters Inhibitors Are Contributory Factors for Drug-Induced Cholestasis.
Chen, X; Jiang, J; Pang, X; Zhong, D; Zhou, L, 2017
)
3.34
"Nimesulide is a non-steroidal anti-inflammatory drug available in several European countries. "( [Acute liver failure due to a treatment by nimesulide: another case and review].
Baillon, JJ; Ber, CE; Christin, F; Delafosse, B; Dumortier, J; Hayi-Slayman, D; Page, M; Rimmelé, T, 2008
)
2.05
"Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) marketed in more than 50 countries. "( In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation.
Chordia, MD; Huang, T; Li, F; Macdonald, TL, 2009
)
2.21
"Nimesulide is a non-steroidal anti-inflammatory agent that is widely used."( The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats.
Camacho-Vieyra, AG; Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ, 2008
)
1.31
"Nimesulide is a non-steroidal anti-inflammatory agent that is widely used in the treatment of inflammatory pain. "( Comparison of suspension composition on the pharmacokinetics of nimesulide in rats.
Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ, 2008
)
2.03
"Nimesulide is a selective cyclooxygenase-2 inhibitor, whose adverse effects on the liver range from acute hepatitis to more serious conditions, involving the development of acute liver failure and fatal outcome."( [Cholestatic hepatitis associated with nimesulide--a case report].
Boricić, I; Damjanov, N; Djuranović, S; Kovacević, N; Krstić, M; Lukić, S; Popović, D; Tomanović, N,
)
1.12
"Nimesulide is a widely prescribed nitroaromatic sulfoanilide-type nonsteroidal anti-inflammatory drug that, despite its favorable safety profile, has been associated with rare cases of idiosyncratic drug-induced liver injury (DILI). "( Nimesulide-induced electrophile stress activates Nrf2 in human hepatocytes and mice but is not sufficient to induce hepatotoxicity in Nrf2-deficient mice.
Boelsterli, UA; Hsiao, CJ; Kale, VM, 2010
)
3.25
"Nimesulide is a non-steroidal anti-inflammatory drug which is frequently used as adjuvant therapy for symptomatic alleviation of rheumatoid arthritis."( Nimesulide improves the disease modifying anti-rheumatic profile of methotrexate in mice with collagen-induced arthritis.
Abdel-Naim, AB; Al-Abd, AM; El-Eraky, WI; Inglis, JJ; Khalifa, AE; Nofal, SM; Williams, RO, 2010
)
2.52
"Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) and a COX-2 inhibitor. "( Phase transformation in conformational polymorphs of nimesulide.
Nangia, A; Sanphui, P; Sarma, B, 2011
)
2.06
"Nimesulide is a frequently used non-steroidal anti-inflammatory drug with analgesic and antipyretic effects in children. "( Fatal bronchiolitis obliterans complicating Stevens-Johnson syndrome following treatment with nimesulide: a case report.
Dogra, S; Rawat, A; Saini, AG; Sodhi, KS; Suri, D, 2011
)
2.03
"Nimesulide is a selective COX-2 inhibitor that is as effective as the classical non-acidic nonsteroidal anti-inflammatory drugs in the relief of various pain and inflammatory conditions, but is better tolerated with lower incidences of adverse effects than other drugs. "( Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects.
Kang, JS; Kim, DW; Kim, MS; Kim, SH; Kim, SY; Kim, YH; Lee, MH; Park, YS; Yang, SC, 2012
)
2.16
"Nimesulide is a COX 2 selective anti-inflammatory that is poorly soluble in water."( Natural lipid nanoparticles containing nimesulide: synthesis, characterization and in vivo antiedematogenic and antinociceptive activities.
Alves, MP; Antonow, MB; Fagan, SB; Lima, A; Lorenzoni, R; Raffin, RP; Turra, C, 2012
)
1.37
"Nimesulide is a non-steroidal anti-inflammatory drug that acts through selective inhibition of COX-2 enzyme. "( Applying response surface methodology to optimize nimesulide permeation from topical formulation.
Afreen, U; Hussain, T; Nisar Hussain Shah, S; Shahzad, Y,
)
1.83
"Nimesulide is a preferential COX-2 inhibitor widely used to treat pain."( Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia.
Greco, R; Nappi, G; Sandrini, G; Tassorelli, C, 2003
)
1.28
"Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) that exhibits analgesic, antipyretic and anti-inflammatory activities. "( Hydrotropic solubilization of nimesulide for parenteral administration.
Agrawal, GP; Agrawal, S; Jain, NK; Pancholi, SS, 2004
)
2.05
"Nimesulide, though it is a relatively safe drug to use in aspirin-sensitive asthmatics, may (like other nonsteroidal anti-inflammatory drugs) cause PIE in asthmatic patients and thus should be used cautiously."( Pulmonary infiltrates with eosinophilia induced by nimesulide in an asthmatic patient.
Lee, YC; Perng, DW; Su, HT; Tseng, CW,
)
1.1
"Nimesulide is a cyclooxygenase (COX) inhibitor with a high degree of selectivity to COX-2. "( Nimesulide-induced fixed drug eruption.
Cadinha, S; Castel-Branco, MG; Malheiro, D; Rodrigues, J; Vaz, M,
)
3.02
"Nimesulide is a new nonsteroidal anti-inflammatory (NSAID) drug with antipyretic and analgesic properties. "( Acute generalized exanthematous pustulosis induced by nimesulide.
Selores, M; Silva, E; Teixeira, M, 2006
)
2.02
"Nimesulide is an NSAID, with cox-2 preference, which has been reported to cause death from hepatic failure."( Nimesulide-induced hepatotoxicity and fatal hepatic failure.
Chow, WC; Lai, SH; Ong, WM; Tan, HH, 2007
)
2.5
"Nimesulide is a typical nonsteroidal anti-inflammatory drug (NSAID), widely used in solid oral formulations. "( Characterization and compaction behaviour of nimesulide crystal forms.
Barthélémy, C; Censi, R; Di Martino, P; Gobetto, R; Joiris, E; Martelli, S; Masic, A; Odou, P, 2007
)
2.04
"Nimesulide is a nonsteroidal antiinflammatory (NSAID) drug whose mechanism of action is characterized by selective inhibition of cyclooxygenase-2. "( [Nimesulide spectrophotometric determination in the visible region].
Dorneanu, V; Mândrescu, M; Perju, AC; Spac, AF,
)
2.48
"Nimesulide is a preferential inhibitor of cyclooxygenase-2 (COX-2) and it is one of the most prescribed non-steroidal anti-inflammatory drugs (NSAID) worldwide. "( Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences.
Candelario-Jalil, E, 2008
)
3.23
"Nimesulide (NIM) is a sulfonanilide nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of various inflammatory diseases and chemically unrelated to other acidic NSAIDs, such as acetylsalicylic acid (ASA) and indomethacin (INDO). "( Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells.
Casolaro, V; de Paulis, A; Guidi, G; Marino, O; Marone, G; Meliota, S; Patella, V, 1993
)
3.17
"Nimesulide is a nonsteroidal anti-inflammatory drug that can modulate the function of neutrophils and block the effects of several inflammatory mediators."( Nimesulide in the treatment of chronic bronchitis.
Carratù, L; Molino, A; Mormile, M; Scaricabarozzi, I; Sofia, M; Stanziola, A, 1993
)
2.45
"Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) of the sulfonanilide class. "( Recent contributions to knowledge of the mechanism of action of nimesulide.
Bevilacqua, M; Magni, E, 1993
)
1.97
"Nimesulide is a nonsteroidal anti-inflammatory agent with additional antipyretic and analgesic activity. "( Effect of age and disease on the pharmacokinetics of nimesulide.
Olive, G; Rey, E, 1993
)
1.98
"Nimesulide is a recently developed analgesic, antipyretic and anti-inflammatory agent that differs from conventional nonsteroidal anti-inflammatory drugs both in structure and pharmacological profile. "( Drug interactions with nimesulide.
Perucca, E, 1993
)
2.04
"Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) administered orally or rectally twice daily for a variety of inflammatory and pain states. "( Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Brogden, RN; Davis, R, 1994
)
3.17
"Nimesulide is a selective inhibitor of cyclooxygenase 2 and has been shown to have a more potent anti-inflammatory action than piroxicam, but be less ulcerogenic and, therefore, a potentially more useful chemopreventive agent."( Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.
Fukutake, M; Ishida, K; Sugimura, T; Takahashi, M; Wakabayashi, K; Yokota, S, 1996
)
1.25
"Nimesulide is a nonsteroidal anti-inflammatory drug, supposed to act by inhibition of phosphodiesterase type IV."( The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils.
Knol, EF; Mul, FP; Roos, D; Tool, AT; Verhoeven, AJ, 1996
)
1.31
"Nimesulide is a nonsteroidal antiinflammatory drug that exhibits a very poor water solubility (0.01 mg.mL-1). "( Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes.
Delarge, J; Delattre, L; Delneuville, I; Llabres, G; Neven, P; Piel, G; Pirotte, B, 1997
)
1.96
"Nimesulide is a nonsteroidal anti-inflammatory drug recently detected in equine blood and urine samples taken at the race track. "( A unique metabolite of nimesulide.
Gouthro, H; Leavitt, R; McIntosh, JM; Sarkar, P,
)
1.88
"Nimesulide is a sulfonanilide compound with anti-inflammatory properties."( In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
Famaey, JP, 1997
)
1.24
"Nimesulide is a potent inhibitor of human monocyte prostaglandin H synthase-2. "( Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings.
Pace, A; Padovano, R; Panara, MR; Patrignani, P; Patrono, C; Renda, G; Rotondo, MT; Santini, G; Sciulli, MG, 1998
)
2.13
"Nimesulide is a new agent of the sulfonanilide class, and is a more selective inhibitor of cyclooxygenase type 2 than of type 1."( Nimesulide-induced acute hepatitis: evidence from six cases.
Büscher, H; De Bondt, J; Desmet, V; Laporta, T; Peeters, P; Roskams, T; Staessen, D; Van Steenbergen, W, 1998
)
2.46
"Nimesulide is a selective COX-2 inhibitor used in a variety of inflammatory, pain and fever states. "( Clinical pharmacokinetics of nimesulide.
Bernareggi, A, 1998
)
2.03
"Nimesulide is a newer non-steroidal anti-inflammatory drug (NSAID) with selective cyclo-oxygenase (COX)-2 blocking property and has demonstrated a potent analgesic and anti-inflammatory activity on oral and rectal administration. "( Comparative analgesic efficacy of nimesulide and diclofenac gels after topical application on the skin.
Gupta, SK; Mathur, P; Sapra, P; Sengupta, S; Velpandian, T, 1998
)
2.02
"Nimesulide 1 is a novel nonsteroidal antiinflammatory drug which inhibits the enzyme cyclooxygenase 2 (COX-2) more selectively than cyclooxygenase 1 (COX-1). "( Structural basis for selective inhibition of COX-2 by nimesulide.
Fabiola, GF; Nagarajan, K; Pattabhi, V, 1998
)
1.99
"Nimesulide is a relatively new non-steroidal anti-inflammatory drug that is gaining popularity in many countries because it is a selective cyclooxygenase 2 inhibitor. "( Nimesulide-induced hepatitis and acute liver failure.
Bar-Meir, S; Brickman, CM; Bruck, R; Farfel, Z; Hassin, D; Mouallem, M; Tanay, A; Weiss, P, 1999
)
3.19
"Nimesulide is a potent non-steroidal anti-inflammatory drug. "( [Toxic hepatitis caused by nimesulide, presentation of a new case and review of the literature].
Domínguez, AB; Espinel, J; Fernández, MJ; Ferreiro, C; Herrera, A; Jorquera, F; Muñoz, F; Olcoz, JL; Ortiz de Urbina, J; Vivas, S, 2000
)
2.05
"Nimesulide is a quite popular non-steroidal anti-inflammatory drug (NSAID), which has been demonstrated to preferentially inhibit cycloxygenase-2 (COX-2), thus exerting milder gastrointestinal and renal side effects. "( Comparative in vitro evaluation of nimesulide-containing preparations on the Italian market.
Bonadeo, D; Butler, D; Foppoli, A; Giordano, F; Maroni, A; Zema, L,
)
1.85
"Nimesulide is a NSAID with good anti-inflammatory, analgesic and antipyretic activities expected of such compounds. "( Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities.
Bennett, A; Villa, G, 2000
)
3.19
"Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cyclo-oxygenase 2 and has been associated with a total of 13 reported cases of severe liver injury including our case."( Fatal hepatoxicity secondary to nimesulide.
Cathomas, G; Fattinger, K; Fox, M; Kullak-Ublick, GA; Merlani, G; Oehen, HP; Renner, EL; Schneemann, M, 2001
)
1.32
"Nimesulide is a nonsteroidal anti-inflammatory agent used orally and rectally for inflammatory disorders."( Evaluation of skin sensitization potential of melatonin and nimesulide by murine local lymph node assay.
Jackson, T; Kanikkannan, N; Shaik, MS; Singh, M, 2001
)
1.27
"Nimesulide is a highly prescribed nonsteroidal anti-inflammatory drug (NSAID) world-wide."( Benzydamine: an alternative nonsteroidal anti-inflammatory drug in patients with nimesulide-induced urticaria.
Di Paola, R; Ferrannini, A; Napoli, G; Nettis, E; Tursi, A, 2002
)
1.26
"Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) applied topically for a variety of conditions characterized by pain and inflammation. "( Comparison of the transdermal absorption of nimesulide from three commercially available gel formulations.
Dayal, P; Kanikkannan, N; Sing, M; Singh, A, 2002
)
2.02
"Nimesulide is a non-steroidal anti-inflammatory agent which has proved to be effective in reducing menstrual discomfort in dysmenorrhoeaic women. "( Distribution of oral nimesulide in female genital tissues.
Macciocchi, A; Monti, T; Pulkkinen, MO; Vuento, M, 1991
)
2.04
"Nimesulide is a new non-steroidal anti-inflammatory drug which seems to be characterized by a low inhibitory action on prostaglandin synthesis and a high inhibitory action on oxygen free radicals production. "( [Nimesulide in the treatment of osteoarthrosis and extra-articular rheumatism].
Altomonte, L; Berchicci, M; Corvino, G; Magarò, M; Mirone, L; Zoli, A, 1989
)
2.63
"Nimesulide is a new non-steroidal anti-inflammatory analgesic agent given orally or rectally on a twice daily basis in a number of inflammatory and pain states. "( Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states.
Brogden, RN; Ward, A, 1988
)
3.16

Effects

Nimesulide has been shown to reduce infarction, improve neurological function, attenuate blood-brain barrier disruption and edema. It has been well tolerated by adult, elderly and paediatric patients in clinical trials and large postmarketing surveillance studies.

ExcerptReferenceRelevance
"Nimesulide has been evaluated in numerous clinical studies in the management of a variety of acute painful conditions. "( An Open-label, Prospective, Multicentric, Cohort Study of Nimesulide/Paracetamol Fixed Drug Combination for Acute Pain Management: Sub-group Analysis.
Gondane, A; Muruganathan, A; Pawar, D; Tiwaskar, M, 2023
)
2.6
"Nimesulide has been widely used to treat fever in children. "( Safety of oral use of nimesulide in children: systematic review of randomized controlled trials.
Gupta, P; Sachdev, HP, 2003
)
2.08
"Nimesulide has been shown to reduce infarction, improve neurological function, attenuate blood-brain barrier disruption and edema, and reduce leukocyte infiltration into the ischemic brain."( Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences.
Candelario-Jalil, E, 2008
)
2.51
"Nimesulide has been well tolerated by adult, elderly and paediatric patients in clinical trials and large postmarketing surveillance studies."( Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Brogden, RN; Davis, R, 1994
)
2.45
"Nimesulide has been chosen due to its weak inhibitory action on cyclooxygenase and its peculiar mechanism of action."( Tolerability of nimesulide in aspirin-sensitive patients.
Andri, G; Andri, L; Betteli, C; Givanni, S; Mezzelani, P; Scaricabarozzi, I; Senna, G, 1994
)
1.36
"Nimesulide, which has been shown by ESR to be inactive as a superoxide quencher, has a rate constant of reaction with HO degree slightly greater than that of its metabolite (3.3 x 10(11) mol-1 l s-1)."( Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide.
Aldini, G; Carini, M; Maffei Facino, R; Morelli, R; Saibene, L, 1995
)
1.24
"A nimesulide-L-lysine salt has also been prepared and increases the aqueous solubility of nimesulide to approximately 5.0-7.5 mg.mL-1."( Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes.
Delarge, J; Delattre, L; Delneuville, I; Llabres, G; Neven, P; Piel, G; Pirotte, B, 1997
)
1.08
"Nimesulide also has additional activities, among them effects on production/action of oxy-radicals and other components of neutrophil activation that may contribute to the spectrum of its anti-inflammatory activity as well as potentially reducing the likelihood of gastrointestinal ulcerogenicity."( Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions.
Rainsford, KD, 1999
)
1.37
"Nimesulide has preferential selectivity for COX-2 over COX-1 in vivo at full therapeutic doses and induces less gastrointestinal damage than that seen with naproxen in the short term."( Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.
Barry, M; Bjarnason, I; Fitzgerald, DJ; Gudjonsson, H; Kay, E; Murray, FE; Oddsson, E; Price, AB; Shah, AA; Sigthorsson, G; Thjodleifsson, B, 2001
)
1.97
"Nimesulide have been studied in a double blind study compared with flurbiprofen, in 98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature."( [Clinical study of the efficacy of and tolerance to nimesulide in suppository formulation in pain-inflammatory pathologies of the ear, nose, and throat].
Lomeo, G; Monea, P; Rossi, M; Scaricabarozzi, I; Trezzani, R; Tringali, G, 1991
)
1.25
"Nimesulide has been employed in maxillofacial surgery so as to assess the drug's anti-pain and anti-inflammatory properties. "( [The nimesulide treatment of inflammation and posttraumatic pain in maxillofacial surgery. A controlled study versus flurbiprofen].
Scaricabarozzi, I; Scolari, G; Vargiu, G, 1990
)
2.24
"Nimesulide has been tested by the Authors on a group of 40 adults patients of both sexes that had undergone oral surgery. "( [Nimesulide and algo-edematous pathology of the oral cavity].
De Francesco, G; Palattella, D, 1990
)
2.63

Actions

Nimesulide may inhibit the proliferation of gastric adenocarcinoma cells SGC7901 through decreasing PGE2 release, and affecting the distribution of cell cycle. It can cause toxicity to mitochondria in vitro, although it is unlikely that the high concentrations required are therapeutically relevant.

ExcerptReferenceRelevance
"Nimesulide: an increase in hepatic ADR reporting was observed after withdrawal of the drug from the Finnish and Spanish markets in 2002."( Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G, 2008
)
1.07
"Nimesulide could inhibit cell growth and induce apoptosis in human hepatocellular carcinoma SMMC-7721 cells via the downregulation of HSP70."( [Downregulation of HSP70 gene expression and apoptosis in human hepatocellular carcinoma SMMC-7721 cells induced by nimesulide in vitro].
Han, SS; Liu, QG; Tu, KS; Wang, J; Yao, YM; Yin, GZ, 2012
)
2.03
"Nimesulide can cause toxicity to mitochondria in vitro, although it is unlikely that the high concentrations required are therapeutically relevant."( Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors.
Boelsterli, UA, 2002
)
2.48
"Nimesulide may inhibit the proliferation of gastric adenocarcinoma cells SGC7901 through decreasing PGE2 release, and affecting the distribution of cell cycle and inducing apoptosis. "( [Influence of selective cyclooxygenase-2 inhibitor on proliferation of human gastric cancer cells].
Huang, JA; Li, JY; Luo, HS; Mei, Q; Tian, G; Yu, BP; Yu, JP, 2002
)
1.76
"Nimesulide could inhibit the tumorigenesis and development of DMBA-induced mammary tumors by inhibition of proliferation and induction of apoptosis. "( [The effect of selective cyclooxygenase-2 inhibitor nimesulide on breast cancer induced by dimethylbenzoic acid in rats].
Guo, GL; Yao, ZX; Zhang, XH, 2005
)
2.02
"Nimesulide had a potency lower than those of celecoxib, and DFU."( Additive interaction of intraperitoneal dexmedetomidine and topical nimesulide, celecoxib, and DFU for antinociception.
Bagcivan, I; Cetin, A; Gulturk, S; Gursoy, S; Karadas, B; Kaya, T; Parlak, A, 2007
)
1.3
"Nimesulide may cause liver damage. "( Nimesulide-induced hepatitis and acute liver failure.
Bar-Meir, S; Brickman, CM; Bruck, R; Farfel, Z; Hassin, D; Mouallem, M; Tanay, A; Weiss, P, 1999
)
3.19
"Nimesulide had lower visual analogue scores (VAS) for haemorrhage and erosive lesions in the stomach (p<0.001) and for mucosal injection in the duodenum (p=0.039)."( Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.
Barry, M; Bjarnason, I; Fitzgerald, DJ; Gudjonsson, H; Kay, E; Murray, FE; Oddsson, E; Price, AB; Shah, AA; Sigthorsson, G; Thjodleifsson, B, 2001
)
1.25
"Nimesulide did not cause any RBC lysis and inhibited this action of tiaprofenic acid by 20-30%, depending on the concentration of nimesulide and the intensity of ultraviolet A light."( Tiaprofenic acid-induced photohemolysis in vitro is inhibited by nimesulide.
Figueiredo, A; Poiares-Baptista, A; Ribeiro, CA; Tavares, P; Teixeria, F, 1992
)
1.24

Treatment

Nimesulide treatment gave rise to fewer and less severe side-effects than flurbiprofen treatment. Treatment with nimesuli did not significantly affect body weight, absolute and relative testis weights, or epididymal sperm number.

ExcerptReferenceRelevance
"Nimesulide treatment improved insulin sensitivity and glycemic control, increased GLP-1, decreased liver lipids and improved FGF-21 in serum."( In vivo antidiabetic activity of nimesulide due to inhibition of amino acid transport.
Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, M; Patel, V; Savsani, H, 2022
)
1.72
"Nimesulide treatment (10 mg/kg) prevented the ethanol withdrawal-induced alterations in the levels of TNF-α, IL-1β, and IL-6 in the hippocampus, prefrontal cortex, and striatum."( Attenuation of the levels of pro-inflammatory cytokines prevents depressive-like behavior during ethanol withdrawal in mice.
Buss, ZS; Doneda, DL; Fernandes, IL; Fraga-Junior, EB; Lima, E; Rios-Santos, F; Rohden, CAH; Vandresen-Filho, S; Ynoue, HN, 2022
)
1.44
"Nimesulide treatment decreased the secretion of MCP-1 and PGE2 from lung cancer cells."( Depletion of tumor-associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin.
Hanaoka, J; Kataoka, Y; Kawaguchi, Y; Ohshio, Y; Okamoto, K; Shiratori, T; Suzuki, T; Ueda, K; Watanabe, A, 2023
)
1.63
"Nimesulide treatment did not cause any significant change in any of the measured hemodynamic parameters."( Four-week administration of nimesulide, a cyclooxygenase-2 inhibitor, improves endothelial dysfunction in the hindlimb vasculature of streptozotocin-induced diabetic rats.
Abdelrahman, AM; Al Suleimani, YM, 2008
)
1.36
"The nimesulide treatment group after injury was treated with nimesulide [6 mg/(kg x d)] in peritoneum."( [The effect of nimesulide on learning and memory function after serve traumatic brain injury in rats].
Zhang, T; Zhang, YX, 2011
)
1.2
"Nimesulide treatment attenuated: (1) the increase in LV mass index; (2) the reduction in end diastolic volume; and (3) the PO-induced increase in myocardial collagen."( Alteration in myocardial prostaglandin D synthase expression in pressure overload-induced left ventricular remodeling in rats.
Claudino, MA; Gardner, JD; Gole, M; Murray, DB; Nagalla, KT, 2012
)
1.1
"Nimesulide pretreatment was found to protect the tissue from enhanced levels of lipid peroxidation, and also stimulated the levels of glutathione-S-transferase (GST) in liver and glutathione reductase in kidneys."( Nimesulide affects antioxidant status during acute lung inflammation in rats.
Khanduja, KL; Sohi, KK, 2003
)
2.48
"Nimesulide pretreatment of Y504F and the quadruple mutant results in an abnormally small amount of wide doublet signal, with no narrow singlet being formed."( Identification of Tyr504 as an alternative tyrosyl radical site in human prostaglandin H synthase-2.
Kulmacz, RJ; Liu, W; Rogge, CE; Tsai, AL; Wang, LH; Wu, G, 2004
)
1.04
"Nimesulide treatment showed a dose-dependent growth-inhibitory effect of A549 tumors with a maximum of 77.7% inhibition at 1500 ppm of nimesulide. "( Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.
Chatterjee, A; Shaik, MS; Singh, M, 2004
)
2.02
"Nimesulide-treated mice showed augmented eosinophilic inflammation, LTC4/D4/E4 concentrations and mucous cell metaplasia."( Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice.
Kondo, M; Nagai, A; Nakata, J; Nohara, M; Takemiya, T; Tamaoki, J; Yamagata, K, 2005
)
1.05
"Nimesulide pretreatment could inhibit O2*-, NO() and lipid peroxidation in AMs."( Nimesulide inhibits lipopolysaccharide-induced production of superoxide anions and nitric oxide and iNOS expression in alveolar macrophages.
Kaushik, G; Khanduja, KL; Pathak, CM; Sohi, KK, 2006
)
2.5
"Nimesulide-treated intestine was elongated beyond control values, in contrast to the shorter indomethacin-treated intestine, but anomalous villous forms were present in both treated groups."( Nimesulide alters cell recruitment into mitosis in murine intestinal crypts without influencing the cell production rate.
Bass, G; Ettarh, RR; McGarvey, MA, 2007
)
2.5
"Nimesulide treatment reduced the growth of UVB-induced tumors both in terms of tumor number and tumor volume."( Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Athar, M; Bickers, DR; Kim, AL; Kopelovich, L; Tang, X,
)
1.15
"Nimesulide treatment showed a dose-dependent growth-inhibitory effect of human ovarian SKOV-3 tumors."( Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.
Hu, YQ; Li, J; Li, W; Xu, RJ; Zhang, HH; Zhuo, GC, 2008
)
1.32
"Nimesulide treatment brought about an immediate and significant improvement in over-all pain, exudation, oedema and headache and produced a rapid lowering in body temperature."( Nimesulide for the treatment of painful inflammatory process in the ear, nose and throat areas: a double-blind controlled study with benzydamine.
Milvio, C, 1984
)
2.43
"Nimesulide treatment for 7 to 10 days is shown to be effective in controlling the inflammatory process in upper airways disorders such as rhinitis, rhinosinusitis, rhinopharyngitis and tubaritis, and in middle ear disorder (secretory otitis media). "( Treatment of upper airways inflammation with nimesulide.
Bellussi, L; Passàli, D, 1993
)
1.99
"Nimesulide treatment was associated with a more rapid and greater antipyretic effect than lysine-acetylsalicylate: 94% of nimesulide recipients and 77% of lysine-acetylsalicylate recipients were considered by physicians to have a good or very good response to therapy (p < 0.05)."( Efficacy and tolerability of nimesulide and lysine-acetylsalicylate in the treatment of paediatric acute upper respiratory tract inflammation.
Cappella, L; Cavazzuti, GB; Guerra, A; Laudizi, L, 1993
)
1.3
"In nimesulide-treated ewes, maternal plasma PGE2 and ACTH concentrations remained unchanged, while maternal plasma cortisol decreased significantly, recovering to baseline by 3 h."( Prostaglandin regulation of fetal plasma adrenocorticotropin and cortisol concentrations in late-gestation sheep.
Bennett, PR; Nathanielsz, PW; Shinozuka, N; Unno, N; Wong, CH; Wu, WX, 1998
)
0.81
"nimesulide-treated groups were 0.70 +/- 0.28 and 0.35 +/- 0.11, respectively, being significantly smaller than the AOM alone value (1.79 +/- 0.47)."( Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice.
Fukuda, K; Fukutake, M; Isoi, T; Mamiya, S; Nakatsugi, S; Ohta, T; Sato, H; Sugimura, T; Takahashi, M; Taniguchi, Y; Wakabayashi, K, 1998
)
1.33
"In 2 nimesulide-treated ewes labor did not progress to delivery despite membrane rupture."( Efficacy of the selective prostaglandin synthase type 2 inhibitor nimesulide in blocking basal prostaglandin production and delaying glucocorticoid-induced premature labor in sheep.
Hirst, JJ; Poore, KR; Young, IR, 1999
)
1
"Four nimesulide- and atosiban-treated ewes successfully completed the 48-hour infusion period with no deliveries occurring during inhibitor treatment, or up to 6 hours after inhibitor treatment. "( Inhibition of prostaglandin synthesis and its effect on uterine activity during established premature labor in sheep.
Grigsby, PL; Hirst, JJ; Jenkin, G; Scott, JE,
)
0.65
"Nimesulide treatment gave rise to fewer and less severe side-effects than flurbiprofen treatment."( Comparison of nimesulide and flurbiprofen in the treatment of non-infectious acute inflammation of the upper respiratory tract.
Cadeddu, L; Piragine, F; Puxeddu, P; Scornavacche, V; Sellari Franceschini, S,
)
1.21
"Treatment of nimesulide with MPTP further potentiated expressions of p62, ATG-5, beclin-1, LC3 autophagic proteins."( Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease.
Mishra, KP; Niranjan, R; Thakur, AK, 2018
)
0.83
"Pretreatment with nimesulide nullified the infarct size sparing effect of E2 (55.8 +/- 5.6)."( Estrogen protects the heart from ischemia-reperfusion injury via COX-2-derived PGI2.
Booth, EA; Flint, RR; Knittel, AK; Lucas, KL; Lucchesi, BR, 2008
)
0.67
"Treatment with nimesulide alone did not produce any significant change in any of the above measurements."( Interaction of nimesulide, a cyclooxygenase-2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats.
Abdelrahman, AM; Al Suleimani, YM; Alhseini, IS; Ali, BH; AlMahruqi, AS; Mansour, ME; Tageldin, MH, 2010
)
1.05
"Pretreatment with nimesulide (10 mg iv, n = 6), a specific inhibitor of PGHS-2, significantly reduced the HPA axis response to NMDA."( Interaction of PGHS-2 and glutamatergic mechanisms controlling the ovine fetal hypothalamus-pituitary-adrenal axis.
Knutson, N; Wood, CE, 2010
)
0.68
"Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1α, IL-1β, and mPGES-1 genes."( Guggulipid and nimesulide differentially regulated inflammatory genes mRNA expressions via inhibition of NF-kB and CHOP activation in LPS-stimulated rat astrocytoma cells, C6.
Nath, C; Niranjan, R; Shukla, R, 2011
)
1.06
"Treatment with nimesulide did not significantly affect body weight, absolute and relative testis weights, or epididymal sperm number, but there were significant differences in testosterone and estradiol levels. "( Effects of nimesulide on testicular functions in prepubertal albino rats.
Ebere, OO; Okwuoma, A; Ugochukwu, AP, 2011
)
1.11
"Treatment with nimesulide reversed the staurosporine-mediated effects on these gene products during protection against apoptosis."( Altered gene expression during nimesulide-mediated inhibition of apoptotic death in human chondrocytes.
Mukherjee, P; Pasinetti, GM, 2002
)
0.94
"Pretreatment with nimesulide for 10 min antagonized the decrease of endothelium-dependent vasodilatation in H2O2-treated group [(-22.2 +/- 4.2) % vs (-6.0 +/- 2.5) %, P<0.01], but had no effect on the decline of endothelium-independent vasodilatation [(-2.0 +/- 1.8)% vs (-7.0 +/- 3.5) %, P>0.05]."( COX-2 inhibitor nimesulide protects rat heart against oxidative stress by improving endothelial function and enhancing NO production.
Chen, WL; Chen, YY; Fan, Y; Lv, PP; Shen, YL; Wang, LL; Zhu, L, 2007
)
1.01
"Treatment with nimesulide did not improve NSS (NSS at 24 h = 11+/-6 [median +/- range] in group 3 and 12+/-4 in group 4) or edema formation (brain water content at 24 h = 84.3+/-1.8% [mean +/- SD] in group 3 and 83.8+/-1.9% in group 4)."( Inhibition of cyclooxygenase 2 by nimesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats.
Artru, AA; Kaplanski, J; Koyfman, L; Rubin, M; Shapira, Y; Talmor, D, 2000
)
0.93
"Pretreatment with nimesulide failed to reduce the fraction of cells that responded to prostaglandin F2alpha. "( Differing mechanisms of inhibition of calcium increases in human uterine myocytes by indomethacin and nimesulide.
Landen, CN; Young, RC; Zhang, P, 2001
)
0.86
"Treatment with nimesulide (10 mg/kg), indomethacin (10 mg/kg), or dexamethasone (1 mg/kg) reduced plasma PGEM concentrations and edema in the inflamed bowel."( Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut.
Kankuri, E; Korpela, R; Moilanen, E; Paakkari, I; Vaali, K; Vapaatalo, H, 2001
)
0.92
"Treatment with nimesulide reduced both the pain and the tumefaction due to the inflammatory pathology more rapidly and, by the 3rd day of treatment led to complete remission of the symptomatology."( [A clinical study of the therapeutic activity and tolerance of nimesulide in a suppository formulation in oral medicine].
Bucci, E; Bucci, P; Lo Muzio, L; Mignogna, MD; Scaricabarozzi, I; Trezzani, R, 1990
)
0.86
"The treatment with nimesulide produced good results in all pathologies, significantly reducing the intensity of symptomatology."( [Multicenter study in the Campania region on the clinical effectiveness and tolerance of nimesulide in gynecologic inflammatory diseases].
Bedoschi, D; Chiantera, A; Scaricabarozzi, I, 1990
)
0.82
"Treatment with nimesulide produced good results in all pathologies, significantly reducing the intensity of symptomatology."( [A Sicilian multicenter study of the clinical effectiveness and tolerability of nimesulide in gynecologic inflammatory diseases].
Bedoschi, D; Di Leo, S; Meli, MT; Scaricabarozzi, I, 1990
)
0.85

Toxicity

Nimesulide is a potential nephrotoxic drug and its toxic effects on kidney can be minimized by using glycosidal extract of Pk. 13 (21.5%) dropped out in the nimesilide group. At the highest dose level, nimeslide 200 mg, the incidence of adverse events was greater although not significantly.

ExcerptReferenceRelevance
" In conclusion, nimesulide appears to be a safe and effective treatment for paediatric patients with pharyngo-amygdalitis and it has shown superior efficacy and tolerability when compared with naproxen."( Assessment of the efficacy and safety of nimesulide vs naproxen in paediatric patients with respiratory tract infections. A comparative single-blind study.
Arista Viveros, HA; Lopez, E; Lujan, ME; Maciel, RM; Salmòn Rodriguez, LE; Trujillo, CL, 1993
)
0.9
" Nimesulide 50 mg and 100 mg were generally well-tolerated but at the highest dose level, nimesulide 200 mg, the incidence of adverse events was greater although not significantly."( Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis.
Bourgeois, P; Dreiser, RL; Lequesne, MG; Macciocchi, A; Monti, T, 1994
)
1.43
"Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs and their use is frequently associated with severe or even serious adverse events, which increase morbidity and mortality."( Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions.
Rainsford, KD, 1999
)
0.65
"5%) dropped out in the nimesulide group (two early recovery, one lack of effect, one adverse event), compared with 13 (21."( Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide.
Wober, W, 1999
)
0.89
" This is due to the lower incidence of gastrointestinal adverse events with nimesulide, and the absence of serious gastrointestinal complications leading to hospitalization, which more than offset the higher acquisition cost of nimesulide."( Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
Liaropoulos, L, 1999
)
0.84
" Results from the present study suggest a better therapeutic index for the nimesulide-piperine combination indicating that this combination would further reduce the frequency of adverse effects associated with nimesulide alone."( Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination.
Bansal, P; Bhardwaj, RK; Gupta, SK; Velpandian, T, 2000
)
0.77
"Paracetamole and codeine are safe alternative analgesics for analgesic intolerant patients."( Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
Kalyoncu, AF; Karakaya, G,
)
0.53
" Mild adverse effects, mainly gastrointestinal, considered possibly related to treatment were recorded in 4 patients treated with nimesulide and in 12 patients treated with piroxicam."( Comparative efficacy and safety of nimesulide versus piroxicam in osteoarthritis with special reference to chondroprotection.
Gulati, P; Gupta, V; Rastogi, S; Rohtagi, D; Sharma, S, 1999
)
0.79
" Based on spontaneous reports to the World Health Organization, nimesulide induces a high proportion of severe adverse hepatic reactions compared with other NSAIDs registered in Switzerland."( Fatal hepatoxicity secondary to nimesulide.
Cathomas, G; Fattinger, K; Fox, M; Kullak-Ublick, GA; Merlani, G; Oehen, HP; Renner, EL; Schneemann, M, 2001
)
0.83
" An example is nimesulide, a selective cyclo-oxygenase-2 inhibitor widely used for the treatment of inflammatory and pain conditions, which has been recently associated with rare but serious and unpredictable adverse reactions in the liver (increases in serum aminotransferase activities, hepatocellular necrosis, and/or intrahepatic cholestasis)."( Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.
Boelsterli, UA, 2002
)
0.92
"Nimesulide, similar to other nonsteroidal anti-inflammatory drugs (NSAIDs), has been associated with rare and unpredictable but serious hepatic adverse reactions."( Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors.
Boelsterli, UA, 2002
)
3.2
"Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events."( Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?
Devière, J, 2002
)
0.31
" Due to reports of adverse drug reactions, discontinuation or modification of its use has been suggested."( Safety of oral use of nimesulide in children: systematic review of randomized controlled trials.
Gupta, P; Sachdev, HP, 2003
)
0.63
"Oral nimesulide is as safe or unsafe as other analgesics-antipyretics for short-term use (less than or equal to 10 d) in children."( Safety of oral use of nimesulide in children: systematic review of randomized controlled trials.
Gupta, P; Sachdev, HP, 2003
)
1.15
"The herein described challenge with alternative drugs, meloxicam and nimesulide, is a safe tool for the management of NSAIDs-intolerant patients."( Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs.
Bonadonna, P; Canonica, GW; Crivellaro, M; Dama, A; Passalacqua, G; Schiappoli, M; Senna, GE, 2003
)
2
" One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs."( Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004
)
0.74
" All patients with asthma tolerated rofecoxib without any adverse effects."( Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004
)
0.53
" Thus, nimesulide is an effective and safe drug for the treatment of PA."( [The effectiveness and safety of nimesulide (nimesile) in patients with gouty arthritis].
Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Karateev, AE; Nasonov, EL; Nasonova, VA; Tsapina, TN, 2004
)
1.06
" The rate of adverse hypersensitivity reactions to these agents is generally low."( Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
D'Amato, G; D'Amato, M; Liccardi, G; Piccolo, A; Piscitelli, E; Salzillo, A; Senna, G, 2005
)
0.55
"We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs."( Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
D'Amato, G; D'Amato, M; Liccardi, G; Piccolo, A; Piscitelli, E; Salzillo, A; Senna, G, 2005
)
0.55
"Cyclooxygenase (COX-2) inhibitors were developed with the hope that they will cause fewer gastrointestinal adverse effects."( Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors.
Malhotra, S; Nada, R; Pandhi, P; Shafiq, N, 2005
)
0.33
"Non-steroidal anti-inflammatory drugs (NSAIDs) and cyclo-oxygenase-2 (cox-2) inhibitors are structurally heterogeneous drugs that share similar therapeutic actions and adverse effects."( Nimesulide-induced hepatotoxicity and fatal hepatic failure.
Chow, WC; Lai, SH; Ong, WM; Tan, HH, 2007
)
1.78
"Osteoarthritis (OA) affects mainly older people who are more sensitive to adverse effects of classic nonsteroidal anti-inflammatory drugs."( Efficacy and safety of topical nimesulide in the treatment of knee osteoarthritis.
Bodur, H; Ergün, H; Külcü, D; Kutlay, S; Tulunay, FC, 2007
)
0.63
" This may produce adverse events in clinical practice if the therapeutic index of that drug is narrow."( Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis.
Ilic, KV; Jankovic, S; Sefik-Bukilica, M; Vujasinovic-Stupar, N,
)
0.39
" Adverse events reported by the patients, or observed by the investigators were recorded."( Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis.
Ilic, KV; Jankovic, S; Sefik-Bukilica, M; Vujasinovic-Stupar, N,
)
0.39
"T and N are equally effective and safe forms of nimesulide for pain management in low back pain and knee osteoarthritis."( Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis.
Ilic, KV; Jankovic, S; Sefik-Bukilica, M; Vujasinovic-Stupar, N,
)
0.65
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"COX-2 inhibitors are safe alternatives in patients with cross-reactive non-steroidal anti-inflammatory drug (NSAID) hypersensitivity."( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z,
)
0.13
"This study included the retrospective analysis of cases with cross-reactive NSAID hypersensitivity who underwent DPTs with COX-2 inhibitors in order to find safe alternatives."( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z,
)
0.13
"Our results suggest to follow the traditional DPT method to introduce COX-2 inhibitors for finding safe alternatives in all patients with cross-reactive NSAID hypersensitivity before prescription as uncertainty of any predictive factor for a positive response continues."( Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Aydın, Ö; Çelik, GE; Demirel, YS; Erkekol, FÖ; Mısırlıgil, Z,
)
0.13
"The safe use of medications in pregnant females, their embryos and in offspring is important."( A toxicology study to evaluate the embryotoxicity of metformin compared with the hypoglycemic drugs, the anticancer drug, the anti-epileptic drug, the antibiotic, and the cyclo-oxygenase (COX)-2 inhibitor.
Chai, Z; Li, L; Liu, C; Shen, X; Wang, L; Zhang, X; Zhang, Z, 2015
)
0.42
"Our study shows that nimesulide is a potential nephrotoxic drug and its toxic effects on kidney can be minimized by using glycosidal extract of Pk."( EVALUATION OF THERAPEUTIC POTENTIAL OF PICRURHIZA KURROA GLYCOSIDAL EXTRACT AGAINST NIMESULIDE NEPHROTOXICITY: A PILOT STUDY.
Aaqil, B; Alam, MA; Alam, SS; Begum, S; Nazneen, Z; Siddiqi, A,
)
0.67
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Combined knowledge of analytical and toxicology assessment will help in developing safe and quality product."( Quantification and In Silico Toxicity Assessment of Nimesulide and its Related Substances.
Ananthula, RS; Gollapalli, NR; Krishnamurthy, T; Nagulakonda, NNM; Susarla, KPC, 2017
)
0.71
" The most common adverse events in the pooled group were abdominal discomfort, abdominal distention, dyspepsia, and nausea, but none of these was deemed to be clinically meaningful."( Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms.
Amazonas, RB; Bocchi de Oliveira, MF; Ecclissato, C; Macêdo, EA; Pott Júnior, H; Scheinberg, M, 2018
)
0.73
" The primary endpoints were dose-limiting toxicities (DLTs) in Cycle 1 as well as serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) throughout the study; secondary endpoints were pharmacodynamics parameters, objective tumor response, and urinary pharmacodynamics markers of target inhibition."( Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023
)
0.91
"Selective COX-2 inhibitor NSAIDs are safe in patients with N-ERD."( Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study.
Çakmak, ME, 2022
)
0.72

Pharmacokinetics

The pharmacokinetic properties and in vitro potency of nimesulide, a nonsteroidal anti-inflammatory drug (NSAID) were investigated in 8 or 10 dogs after intravenous (i.e. IV) injection. The pharmacokinetics profile and efficacy of ninesulide were assessed in 2 separate studies that recruited children with hypoglycaemia or upper respiratory tract infection and fever.

ExcerptReferenceRelevance
"The pharmacodynamic and pharmacokinetic interactions were studied between nimesulide, a recently introduced non-steroidal anti-inflammatory drug, and theophylline, another highly protein-bound drug, in patients who were receiving slow-release theophylline for a chronic airflow-obstruction and who also needed anti-inflammatory treatment."( Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide.
Auteri, A; Blardi, P; Bruni, F; Di Perri, T; Domini, L; Pasqui, AL; Saletti, M; Scaricabarozzi, I; Vargui, G; Verzuri, MS, 1991
)
0.73
"The pharmacokinetic pattern of 100 mg nimesulide administered rectally at different times prior to undergoing minor surgery was studied in 45 children."( Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation.
Brülhart, K; Monti, T; Schärli, AF,
)
0.66
"The pharmacokinetic profile and efficacy of nimesulide were assessed in 2 separate studies that recruited children with hypoglycaemia or upper respiratory tract infection and fever, respectively."( Clinical and pharmacokinetic study of nimesulide in children.
Berardi, M; Guarnaccia, S; Renzetti, I; Ugazio, AG, 1993
)
0.82
" The pharmacokinetic profile of nimesulide and its hydroxy metabolite was not altered when the drug was administered in a standard regimen (100mg twice daily) to elderly patients aged < 80 years, suggesting that dosage adjustment is not necessary for such patients."( Effect of age and disease on the pharmacokinetics of nimesulide.
Olive, G; Rey, E, 1993
)
0.82
" However, it has a pharmacodynamic profile suggestive of a possibly reduced propensity to cause adverse gastrointestinal effects, although this has not been conclusively demonstrated in comparative clinical trials, many of which showed a similar incidence of such effects for nimesulide and the comparator agent."( Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Brogden, RN; Davis, R, 1994
)
1.91
" Its use for pharmacokinetic studies has been evaluated."( High-performance thin-layer chromatography for the determination of nimesulide in human plasma, and its use in pharmacokinetic studies.
Chakravarthy, BK; Gandhi, TP; Modi, IA; Modi, RI; Pandya, KK; Satia, MC, 1997
)
0.53
" The aim of the present study was to evaluate the comparative efficacy of intramuscularly injected nimesulide with that of diclofenac and to elucidate the pharmacokinetic profile of this formulation."( Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide.
Gupta, SK; Mathur, P; Sengupta, S; Velpandian, T, 1998
)
0.8
" When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations."( Clinical pharmacokinetics of nimesulide.
Bernareggi, A, 1998
)
1.07
" The analgesic activity of nimesulide was subsequently correlated with its pharmacokinetic profile."( Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo.
Gupta, SK; Kabir, SR; Sengupta, S; Velpandian, T, 1998
)
0.85
" Peak analgesic effect was observed at 120 min post-treatment, which correlated with the pharmacokinetic profile of the drug in gel formulation."( Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo.
Gupta, SK; Kabir, SR; Sengupta, S; Velpandian, T, 1998
)
0.55
"The superior analgesic activity of nimesulide (as gel formulation), correlating with its pharmacokinetic profile, indicates that the topical route of administration may be a safe and effective alternative to the presently used oral and rectal routes."( Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo.
Gupta, SK; Kabir, SR; Sengupta, S; Velpandian, T, 1998
)
0.83
" The present study was designed to evaluate the anti-inflammatory activity of a new parenteral formulation of nimesulide and to correlate it with the pharmacokinetic profile."( Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide.
Bhardwaj, RK; Gupta, SK; Sengupta, S; Tyagi, P; Velpandian, T, 1999
)
0.74
"The pharmacokinetic properties and in vitro potency of nimesulide, a nonsteroidal anti-inflammatory drug (NSAID) were investigated in 8 or 10 dogs after intravenous (i."( Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog.
Cester, CC; Haak, T; Metge, S; Toutain, PL, 2001
)
0.79
" Plasma was separated and assayed for lithium by M 654 Na+/K+/Li+ analyzer and various pharmacokinetic parameters were calculated."( Effect of nimesulide co-administration on pharmacokinetics of lithium.
Garg, SK; Kondal, A; Malhotra, S; Pandhi, P; Sidhu, S, 2004
)
0.73
" To minimize the risk, careful pharmacokinetic studies are desired in the pre-registration period and afterwards."( A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers.
Jovanović, D; Kilibarda, V; Potrebić, O; Todorović, V, 2005
)
0.56
" Analysis of variance, power analysis, 90% confidence intervals, and two one-sided tests were used for the statistical analysis of pharmacokinetic parameters."( A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers.
Jovanović, D; Kilibarda, V; Potrebić, O; Todorović, V, 2005
)
0.56
"The pharmacokinetic properties and bioavailability of cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drug nimesulide were investigated in female goats following intravenous (i."( Pharmacokinetics and bioavailability of nimesulide in goats.
Malik, JK; Rao, GS; Shankaramurthy, NC; Siddaraju, VB, 2007
)
0.81
" Compartmental and noncompartmental pharmacokinetic analyses were performed."( Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.
Belloli, C; Cagnardi, P; Carli, S; Ferro, E; Villa, R; Zizzadoro, C; Zonca, A, 2007
)
0.61
" In order to establish if malnutrition can modify the pharmacokinetics of nimesulide, a comparison of pharmacokinetic parameters obtained in control and protein-calorie malnourished rats was carried out."( The influence of malnutrition on the oral pharmacokinetics of nimesulide in rats.
Camacho-Vieyra, AG; Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ, 2008
)
0.82
" Results established selectivity and suitability of the method for pharmacokinetic studies of curcumin from C-SLNs."( Pharmacokinetic applicability of a validated liquid chromatography tandem mass spectroscopy method for orally administered curcumin loaded solid lipid nanoparticles to rats.
Chauhan, AS; Kakkar, V; Kaur, IP; Sahwney, S; Singh, G; Singh, S; Singla, D, 2010
)
0.36
"High-throughput analysis of a large number of samples for pharmacokinetic study is necessary in drug development and pharmacovigilance."( FT-NIR spectroscopy for rapid and simple determination of nimesulide in rabbit plasma for pharmacokinetic analysis.
Ajayakumar, PV; Chanda, D; Pal, A; Samad, A; Singh, MP, 2012
)
0.62
" Pharmacokinetic studies demonstrate the good bioavailability of the compound."( From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Cai, X; Chennamaneni, S; Dowlati, A; Liu, L; Pink, JJ; Su, B; Xu, Y; Yi, X; Zhong, B; Zhou, A, 2012
)
0.7
" The pharmacokinetic parameters were calculated using a noncompartmental model."( Comparison of pharmacokinetics in beagle dogs of nimesulide bilayer tablets with dispersible tablets.
Bai, XQ; Fan, YZ; Gao, CS; Guo, JF; Li, Y; Shan, L; Wang, YL; Yang, MY, 2013
)
0.64
" Several pharmacokinetic parameters were represented: AUC(0-infinity) = 113."( Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects.
Kang, JS; Kim, DW; Kim, MS; Kim, SH; Kim, SY; Kim, YH; Lee, MH; Park, YS; Yang, SC, 2012
)
0.71
" The program simulates the drug delivery and transport by means of (I) a six-compartment physiological pharmacokinetic flow model, (II) a system of traditional compartment models, or (III) a target-mediated drug disposition system."( Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.
Andersson, K; Gabrielsson, J; Ingvast-Larsson, C; Jirstrand, M; Tobin, G, 2014
)
0.4
" By applying the pharmacokinetic determination into human samples, we preliminarily detected a new metabolite of nimesulide (M4*), and the concentration of M4* was relatively higher in plasma."( Simultaneous determination of nimesulide and its four possible metabolites in human plasma by LC-MS/MS and its application in a study of pharmacokinetics.
Chen, Q; Ding, YF; Jiao, XY; Sun, X; Xu, L; Xue, KL; Zheng, H, 2016
)
0.93
" Pharmacokinetic parameters were calculated by using the WinNonlin software."( Pharmacokinetic variations of nimesulide in mongrel dogs according to age.
Álvarez, GR; Brisuela, ON; Espinosa, RL; Garcidueñas, CL; Guillé, PBE; Guillé, PG; Juárez-Olguín, H; Luna, JMA; Medina, AR; Pacheco, CJL; Portugal, CM; Rosales, SRE, 2019
)
0.8

Compound-Compound Interactions

5-ASA suppressed the proliferation of HT-29 colon carcinoma cells more than either of these agents in a dose-dependent and time-dependent manner. These results suggest that caution should be exercised when nimesulide is used in combination with drugs that are known to adversely affect renal haemodynamics.

ExcerptReferenceRelevance
" These results suggest that caution should be exercised when nimesulide is used in combination with drugs that are known to adversely affect renal haemodynamics."( Drug interactions with nimesulide.
Perucca, E, 1993
)
0.84
"To study the effects of cyclooxygenase 2 selective inhibitor Nimesulide (NIM) combined with Cisplatin (DDP) on human lung cancer and the possible mechanisms, the proliferation and apoptosis of human lung cancer cell line A549 were evaluated by MTT reduction assay and flow cytometry respectively."( The effects of nimesulide combined with cisplatin on lung cancer.
Liu, J; Xing, L; Xu, Y; Zhang, H; Zhang, Z, 2004
)
0.92
"To investigate the effects of 5-aminosalicylic acid (5-ASA) in combination with nimesulide on the proliferation of HT-29 colon carcinoma cells and its potential mechanisms."( 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro.
Fang, HM; Ma, WJ; Mei, Q; Xu, JM, 2007
)
0.83
" 5-ASA in combination with nimesulide suppressed the proliferation of HT-29 colon carcinoma cells more than either of these agents in a dose-dependent and time-dependent manner (t=5."( 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro.
Fang, HM; Ma, WJ; Mei, Q; Xu, JM, 2007
)
0.9
" A Phase 1, 2-part (dose escalation, dose expansion), non-randomized, open-label, first-in-human study of CA102N, as monotherapy and in combination with trifluridine-tipiracil, was conducted in patients with locally advanced or metastatic solid tumors."( Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023
)
0.91
" However, there is limited Indian data available on the nimesulide/paracetamol fixed drug combination (FDC)."( An Open-label, Prospective, Multicentric, Cohort Study of Nimesulide/Paracetamol Fixed Drug Combination for Acute Pain Management: Sub-group Analysis.
Gondane, A; Muruganathan, A; Pawar, D; Tiwaskar, M, 2023
)
1.4

Bioavailability

There is some evidence that nimesulide may decrease the oral bioavailability of furosemide (frusemide). A new kind of proline-derivative templated mesoporous silica with curved channels (CMS) was biomimetically synthesized and applied as carrier.

ExcerptReferenceRelevance
" When administered in suppository form, nimesulide peak plasma concentrations were lower and occurred later than those achieved after oral administration; the bioavailability of nimesulide given by suppository ranged from 54 to 96%, relative to that of orally administered formulations."( The pharmacokinetic profile of nimesulide in healthy volunteers.
Bernareggi, A, 1993
)
0.84
" With regard to absorption, there is some evidence that nimesulide may decrease the oral bioavailability of furosemide (frusemide)."( Drug interactions with nimesulide.
Perucca, E, 1993
)
0.84
" dapsone, nimesulide and sulphapyridine, have the potential to reduce the bioavailability of neutrophil-derived HOCl and, in turn, to favour the alpha 1-antitrypsin-dependent control of neutrophil elastolytic activity."( Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation?
Balbi, A; Bevilacqua, M; Dallegri, F; Dapino, P; Ottonello, L; Scirocco, MC, 1995
)
0.69
" When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations."( Clinical pharmacokinetics of nimesulide.
Bernareggi, A, 1998
)
1.07
" Preliminary pharmacokinetic studies conducted by us suggested the increased bioavailability of nimesulide co-administered with piperine."( Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination.
Bansal, P; Bhardwaj, RK; Gupta, SK; Velpandian, T, 2000
)
0.76
" Its poor aqueous solubility poses bioavailability problems in-vivo."( Nimesulide: some pharmaceutical and pharmacological aspects--an update.
Chawla, M; Singh, A; Singla, AK, 2000
)
1.75
"1 h postadministration and the systemic bioavailability was 69 +/- 22%."( Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog.
Cester, CC; Haak, T; Metge, S; Toutain, PL, 2001
)
0.54
" The results suggest that the Nimulid gel may have a greater bioavailability of nimesulide compared to the other gels."( Comparison of the transdermal absorption of nimesulide from three commercially available gel formulations.
Dayal, P; Kanikkannan, N; Sing, M; Singh, A, 2002
)
0.8
"In light of improving the bioavailability of poorly water-soluble drugs, this work focused on the comparison among different nimesulide formulations resorting to in vitro absorption experiments through everted rat intestine."( In vitro nimesulide absorption from different formulations.
Coceani, N; Grassi, M; Meriani, F; Sirotti, C; Voinovich, D, 2004
)
0.95
" The pharmacokinetics and relative bioavailability of three different pharmaceutical formulations containing nimesulide, manufactured by the same pharmaceutical factory, were studied prospectively in 12 healthy subjects of both sexes."( A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers.
Jovanović, D; Kilibarda, V; Potrebić, O; Todorović, V, 2005
)
0.78
"The pharmacokinetic properties and bioavailability of cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drug nimesulide were investigated in female goats following intravenous (i."( Pharmacokinetics and bioavailability of nimesulide in goats.
Malik, JK; Rao, GS; Shankaramurthy, NC; Siddaraju, VB, 2007
)
0.81
"5 mg/kg bwt) were investigated, effects of feeding status on bioavailability determined, and plasma protein binding of the drug and its principal metabolites measured."( Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.
Belloli, C; Cagnardi, P; Carli, S; Ferro, E; Villa, R; Zizzadoro, C; Zonca, A, 2007
)
0.61
" In this study, the rate of absorption of NM from ODT was faster than that from the reference tablet, had a significantly higher (p=0."( In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
Ahmed, IS; Shamma, RN; Shoukri, RA, 2009
)
0.63
" It has been established that complex formation of insoluble substances with cyclodextrins may increase their oral bioavailability since solubility is improved."( Comparison of suspension composition on the pharmacokinetics of nimesulide in rats.
Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ, 2008
)
0.58
" The analytical method was applied to evaluate the pharmacokinetic and relative bioavailability of two different pharmaceutical formulations containing nimesulide, one tablet and one oral suspension, manufactured by the same pharmaceutical factory, comparing with two reference Nisulid formulations in 52 volunteers of both sexes previously divided in two groups of 26 subjects (13 men and 13 females each group)."( Bioavailability of two oral suspension and two oral tablet formulations of nimesulide 100 mg in healthy Brazilian adult subjects.
Borges, BC; Carter Borges, N; Moreno, RA; Orpineli, E; Rigato, HM; Sverdloff, CE, 2010
)
0.79
" Pharmacokinetic studies demonstrate the good bioavailability of the compound."( From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Cai, X; Chennamaneni, S; Dowlati, A; Liu, L; Pink, JJ; Su, B; Xu, Y; Yi, X; Zhong, B; Zhou, A, 2012
)
0.7
"Lipid nanoparticles are drug delivery systems able to increase bioavailability of poorly soluble drugs."( Natural lipid nanoparticles containing nimesulide: synthesis, characterization and in vivo antiedematogenic and antinociceptive activities.
Alves, MP; Antonow, MB; Fagan, SB; Lima, A; Lorenzoni, R; Raffin, RP; Turra, C, 2012
)
0.65
" Poor bioavailability of this drug may leads to local toxicity at the site of aggregation and hinders reaching desired therapeutic effects."( Applying response surface methodology to optimize nimesulide permeation from topical formulation.
Afreen, U; Hussain, T; Nisar Hussain Shah, S; Shahzad, Y,
)
0.38
"Herein a new kind of proline-derivative templated mesoporous silica with curved channels (CMS) was biomimetically synthesized and applied as carrier to improve the drug dissolution and bioavailability of hydrophobic diazepam (DZP) and nimesulide (NMS)."( Biomimetic synthesis of proline-derivative templated mesoporous silica for increasing the brain distribution of diazepam and improving the pharmacodynamics of nimesulide.
Cong, J; Li, H; Li, J; Li, S; Liu, H; Wang, J; Wei, C; Yang, M, 2017
)
0.83
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Nimesulide can be used safely as a long-term analgesic in dogs, but, the dosing regimens in humans should be different when administered at early age.

ExcerptRelevanceReference
" The last dosage was repeated every 12 hrs for 4 times more."( [The epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Nimesulide is tolerated by patients with adverse reactions to NSAIDs and modulates in man the skin response to histamine and codeine].
Altucci, P; Astarita, C; Ferrara, AM; Franzese, A; Raucci, G; Scala, G; Sproviero, S, 1992
)
0.51
" The efficacy of both drugs was judged by the physicians to be good or very good in 70% of cases and there were no statistically significant differences between the two treatment groups in the dosage required or the pain relief."( Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation.
Brülhart, K; Monti, T; Schärli, AF,
)
0.39
" Nimesulide was administered at a daily dosage of 200 mg."( [Nimesulide in the treatment of osteoarthrosis and extra-articular rheumatism].
Altomonte, L; Berchicci, M; Corvino, G; Magarò, M; Mirone, L; Zoli, A, 1989
)
2.1
" On completion of treatment, 1 patient in each nimesulide dosage group and 2 in the control group showed evidence of gastric injury: 1 patient with slight hyperaemic gastropathy at baseline developed superficial ulcerations after treatment with nimesulide 100mg, and 1 patient with a history of gastric ulcer developed a congested corpus mucosa with several erosions and ulcerations after treatment with nimesulide 200mg; in the placebo group, 1 patient developed hyperaemic antropathy and another patient developed several petechiae and microerosions."( Gastric tolerability of nimesulide. A double-blind comparison of 2 oral dosage regimens and placebo.
Marini, U; Spotti, D, 1993
)
0.85
" The second treatment period was always at a higher dosage level than the first."( Renal and general tolerability of repeated doses of nimesulide in normal subjects.
Dawnay, A; Ravic, M; Warrington, SJ, 1993
)
0.54
" The recommended dosage is 100 to 200 mg twice daily orally or rectally."( Effect of age and disease on the pharmacokinetics of nimesulide.
Olive, G; Rey, E, 1993
)
0.54
" Oral granules of nimesulide were administered in daily dosage of 200 mg."( [Controlled clinical study of the efficacy and tolerability of methoxybutropate compared to nimesulide in gynecology].
Ajossa, S; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM, 1997
)
0.85
"The anti-inflammatory effects of therapeutic dosing of drugs with greater selectivity for the inhibition of the constitutive (COX-1) or inducible isoform (COX-2) of cyclooxygenase were assessed in a model of chronic inflammation."( Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation.
Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998
)
0.3
" NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform."( Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation.
Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998
)
0.68
" pD2 values and maximum percentage increases in contractile tension were derived from dose-response curves to 10(-9) to 10(-5) mol/L PGE2 and PGE2 alpha, and 10(-11) to 10(-7) mol/L oxytocin."( In vivo administration of nimesulide, a selective PGHS-2 inhibitor, increases in vitro myometrial sensitivity to prostaglandins while lowering sensitivity to oxytocin.
Baguma-Nibasheka, M; Nathanielsz, PW,
)
0.43
"98 per patient depending on the dosage of diclofenac used."( Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece.
Diamantopoulos, E; Ifandi, G; Ignatiades, T; Katostaras, F; Liaropoulos, L; Spinthouri, M, 1998
)
0.61
" Blood samples were taken before and up to 6 h after dosing and the plasma obtained from it was tested for its ability to inhibit prostanoid formation in IL-1beta-treated A549 cells (COX-2 system) and human washed platelets (COX-1 system)."( Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Giuliano, F; Warner, TD, 1999
)
0.3
"Two simple and accurate ultraviolet (UV) spectrophotometric methods with better detection range for estimation of nimesulide in pure form and in solid dosage form were developed in the present studies using 50% v/v and 100% v/v acetonitrile as the solvent system."( New Ultraviolet spectrophotometric method for the estimation of nimesulide.
Chandran, S; Priya, KP; Saggar, S; Saha, RN, 2000
)
0.76
" Only a limited number of assay procedures (HPLC, spectrophotometric, spectrofluorimetric) for the determination of nimesulide and its metabolite in plasma/urine samples or in dosage forms have been reported in the literature."( Nimesulide: some pharmaceutical and pharmacological aspects--an update.
Chawla, M; Singh, A; Singla, AK, 2000
)
1.96
" As a result, drugs that have little or no COX-1 activity across their therapeutic dosage range have been developed."( COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?
Hawkey, CJ; Jackson, LM, 2000
)
0.31
" To address this hypothesis, we used dosing with nimesulide, which inhibited COX-2 ex vivo, depressed urinary 2,3 dinor 6-keto PGF(1alpha) by approximately 60% but had no effect on thromboxane formation by platelets, which only express COX-1."( Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
FitzGerald, GA; Li, H; Praticò, D; Tillmann, C; Zhang, ZB, 2001
)
0.57
"The present experiment was designed to determine a dosage regimen (dose, interval of administration) in the dog for nimesulide, a nonsteroidal anti-inflammatory drug with in vitro selectivity for the inhibition of cyclo-oxygenase 2 (Cox-2), using a pharmacokinetic/pharmacodynamic (PK/PD) approach."( A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog.
Cester, CC; Haak, T; Laroute, V; Toutain, PL, 2001
)
0.73
"The aim of this study was to compare nimesulide-beta-cyclodextrin and naproxen in terms of short-term (2 weeks) pain control with scheduled dosing and medium-term (5."( A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis.
Bisogno, S; Di Martino, S; Fioravanti, A; Marcolongo, R; Oldani, V; Scotti, A; Storri, L, 2002
)
0.84
" The primary outcome measures for scheduled dosing were pain on movement (measured by visual analog scale), morning stiffness score, Lequesne index, and adverse events."( A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis.
Bisogno, S; Di Martino, S; Fioravanti, A; Marcolongo, R; Oldani, V; Scotti, A; Storri, L, 2002
)
0.57
" On-demand dosing may be an effective and well-tolerated low-dose regimen of nonsteroidal anti-inflammatory drugs for the maintenance of pain control in OA in the medium term."( A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis.
Bisogno, S; Di Martino, S; Fioravanti, A; Marcolongo, R; Oldani, V; Scotti, A; Storri, L, 2002
)
0.57
" Rats were dosed with nimesulide (COX-2 inhibitor), aminoguanidine (iNOS inhibitor), or vehicle."( Neuroinflammatory role of prostaglandins during experimental meningitis: evidence suggestive of an in vivo relationship between nitric oxide and prostaglandins.
Boje, KM; Jaworowicz, D; Raybon, JJ, 2003
)
0.63
" The method is suitable not only for the estimation of active ingredients in pharmaceutical dosage forms but also in vitro estimations in human plasma."( Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids.
Meena, S; Nagaraju, D; Rao, AR; Rao, RN, 2005
)
0.33
" The results of multiple linear regression analysis revealed that for obtaining a rapidly disintegrating dosage form, tablets should be prepared using an optimum concentration of camphor and a higher percentage of crospovidone."( Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique.
Agrawal, R; Amin, A; Bariya, N; Dave, R; Gohel, M; Patel, M, 2004
)
0.56
" After three days, a cumulative dosage of 200 mg of CE in refracted doses were given."( Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
D'Amato, G; D'Amato, M; Liccardi, G; Piccolo, A; Piscitelli, E; Salzillo, A; Senna, G, 2005
)
0.55
" Serum samples, obtained before dosing and at various appropriate time points up to 15 hours, were analyzed for nimesulide content by a high-performance liquid chromatographic method with ultraviolet (LU) detection."( A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers.
Jovanović, D; Kilibarda, V; Potrebić, O; Todorović, V, 2005
)
0.77
" The semisolid dosage forms showed yellowish, glossy and homogeneous aspect after the incorporation of the colloidal suspensions and nanoemulsion."( Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: development and rheological characterization.
Alves, PM; Guterres, SS; Pohlmann, AR, 2005
)
0.59
"To determine the effective COX selectivity of nimesulide in the horse, and suggest a suitable dosing schedule."( Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.
Belloli, C; Cagnardi, P; Carli, S; Ferro, E; Villa, R; Zizzadoro, C; Zonca, A, 2007
)
0.87
" The plasma concentration-time profile was used, together with in vitro literature data on nimesulide inhibition of COX isoforms, to determine the effective COX selectivity of nimesulide in the horse, and suggest a suitable dosing schedule."( Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.
Belloli, C; Cagnardi, P; Carli, S; Ferro, E; Villa, R; Zizzadoro, C; Zonca, A, 2007
)
0.83
"5 mg/kg bwt may produce adequate clinical effects, and the dosing interval should be 12-24 h depending on condition severity."( Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.
Belloli, C; Cagnardi, P; Carli, S; Ferro, E; Villa, R; Zizzadoro, C; Zonca, A, 2007
)
0.61
" Thus, the solubilizing power, dissolution-enhancing effect, and analgesic effect enhancer ability toward the drug make Tris particularly suitable for developing a reduced-dose, fast-release solid oral dosage form of nimesulide."( Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide.
Abdallah, OY; Abdelkader, H; Salem, HS, 2007
)
0.73
"Different dosage volatile oil had no acute toxicity, irritation or hypersensitive effects."( [Study on skin toxicology and penetration enhancement of skin absorption of volatile oil extracted from tender branchers of Camellia oleifera].
Long, ZH; Yang, XZ; Yang, ZC, 2007
)
0.34
"The dissolution test for oral dosage forms has recently widened to a variety of special dosage forms such as suspensions."( Development and validation of a discriminative dissolution test for nimesulide suspensions.
da Fonseca, LB; de Sousa, VP; Labastie, M; Volpato, NM, 2009
)
0.59
"The objective of this study was to formulate stable and controlled release microparticles for simultaneous delivery and UV spectrophotometric detection in combined dosage of an non-steroidal anti-inflammatory drug (NSAID) (nimesulide, NMS) and a spasmolytic agent (tizanidine, TZN) to maintain plasma concentration that may increase patients compliance, improved therapeutic efficacy, The aim was also to reduce severity of upper GI side effects of NMS because of alteration in delivery pattern via slow release of drug from microparticles and to increase the benefits of spasticity and disability for spastic patients by administering TZN in a modified release formulation as these two drugs are often prescribed in combination for the management of pain associated with muscles spasm."( Formulation of two-drug controlled release non-biodegradable microparticles for potential treatment of muscles pain and spasm and their simultaneous spectrophotometeric estimation.
Aamir, MN; Ahmad, M; Akhtar, N; Khan, SA; Kousar, R; Murtaza, G,
)
0.32
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" These studies suggest that there is a possibility that high dosage of caffeine can harm the unborn baby or new born babies, if the mothers use caffeine."( Effect of caffeine, norfloxacin and nimesulide on heartbeat and VEGF expression of zebrafish larvae.
Agoramoorthy, G; Chakraborty, C; Hsu, CH; Lin, CS; Wen, ZH, 2011
)
0.64
" Intraperitoneal injection with a dosage of 5  mg/kg/d of CSUOH0901 to nude mice suppresses HT29 colorectal xenograft growth."( From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Cai, X; Chennamaneni, S; Dowlati, A; Liu, L; Pink, JJ; Su, B; Xu, Y; Yi, X; Zhong, B; Zhou, A, 2012
)
0.7
" Their combination as stroke treatment has the potential benefits of decreasing individual drug dosage and fewer adverse effects."( Magnesium sulfate and nimesulide have synergistic effects on rescuing brain damage after transient focal ischemia.
Huang, CY; Tsai, KJ; Wang, HK; Wang, LC; Wu, MH, 2012
)
0.69
" This study developed a robust method for quantification of nimesulide for the pharmacokinetics and suitability of its dosage in Korea and compared its suitability with other racial populations."( Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects.
Kang, JS; Kim, DW; Kim, MS; Kim, SH; Kim, SY; Kim, YH; Lee, MH; Park, YS; Yang, SC, 2012
)
0.96
"In vitro dissolution methodologies that adequately capture the oral bioperformance of solid dosage forms are critical tools needed to aid formulation development."( Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus.
Amidon, GE; Amidon, GL; Gao, P; Mudie, DM; Ping, H; Shi, Y, 2012
)
0.38
"In this study, a simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination of nimesulide (NS), phenylephrine hydrochloride (PE), chlorpheniramine maleate (CPM) and caffeine anhydrous (CF) in pharmaceutical dosage forms."( Development and validation of RP-HPLC method for simultaneous estimation of nimesulide, phenylephrine hydrochloride, chlorpheniramine maleate and caffeine anhydrous in pharmaceutical dosage form.
Kumar, A; Nair, A; Saini, G; Sharma, R,
)
0.56
" One group was given only PK while the other three groups were given nimesulide in a dosage of 750 mg/kg body weight for 3 days to induce nephrotoxicity and protective effect of Pk was noted by giving 250 mg/kg and 500 mg/kg pk for 14 days to the two of the nimesulide induced nephrotoxicity groups."( EVALUATION OF THERAPEUTIC POTENTIAL OF PICRURHIZA KURROA GLYCOSIDAL EXTRACT AGAINST NIMESULIDE NEPHROTOXICITY: A PILOT STUDY.
Aaqil, B; Alam, MA; Alam, SS; Begum, S; Nazneen, Z; Siddiqi, A,
)
0.59
"The transdermal dosage forms presented a limited usage for a long time, for it was believed that the stratum corneum, the outermost layer of epidermis, made it impracticable the permeation of medications through the skin."( Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs.
Brandao, MAF; de Oliveira Ferreira, A; Pelisson E Silva, TCC; Pereira, RO; Polonini, HC; Raposo, NRB, 2017
)
0.68
"Understanding the phase behavior of active pharmaceutical ingredients is important for formulations of dosage forms and regulatory reasons."( Pressure-temperature phase diagram of the dimorphism of the anti-inflammatory drug nimesulide.
Barrio, M; Céolin, R; Huguet, J; Rietveld, IB; Robert, B; Tamarit, JL, 2017
)
0.68
" The proposed method was validated according to the ICH guidelines and was successfully applied to the analysis of these drugs in their tablet dosage forms with high accuracy."( Simultaneous Determination of Tizanidine, Nimesulide, Aceclofenac and Paracetamol in Tablets and Biological Fluids Using Micellar Liquid Chromatography.
Belal, F; Derayea, S; Hammad, MA; Omar, MA; Saleh, SF; Zayed, S, 2018
)
0.75
" Nimesulide was given in a dosage of 750 mg/kg body weight for 3 days to induce nephrotoxicity and protective effect of Picrorhiza kurroa was noted in two doses of 250 mg/kg and 500 mg/kg for 14 days."( Mechanism Of Nephroprotection By Picrorhiza Kurroa.
Alam, SS; Nazneen, Z; Siddiqi, A; Tariq, S,
)
1.04
" Resulting data suggest that nimesulide can be used safely as a long-term analgesic in dogs, but, the dosing regimens in humans should be different when administered at early age."( Pharmacokinetic variations of nimesulide in mongrel dogs according to age.
Álvarez, GR; Brisuela, ON; Espinosa, RL; Garcidueñas, CL; Guillé, PBE; Guillé, PG; Juárez-Olguín, H; Luna, JMA; Medina, AR; Pacheco, CJL; Portugal, CM; Rosales, SRE, 2019
)
1.09
" Both vultures dosed with nimesulide died within 30 h, after showing outward signs of toxicity and increases in biochemical indicators of renal failure."( The non-steroidal anti-inflammatory drug nimesulide kills Gyps vultures at concentrations found in the muscle of treated cattle.
Alderson, D; Duncan, N; Galligan, TH; Green, RE; Li, Y; Mallord, JW; Naidoo, V; Taggart, MA; Wolter, K, 2022
)
1.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (91)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.71680.003245.467312,589.2998AID1705; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency8.91250.004023.8416100.0000AID489007
Chain A, Beta-lactamaseEscherichia coli K-12Potency15.84890.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency30.13130.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency22.38720.01846.806014.1254AID624172
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.52060.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493106
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency20.82120.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency24.06820.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency60.88100.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency6.58120.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.32890.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency19.06780.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency68.58960.000417.946075.1148AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency12.84690.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.36630.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.36910.000229.305416,493.5996AID1259244; AID743069; AID743075
GVesicular stomatitis virusPotency13.80290.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.50120.001019.414170.9645AID743191
alpha-galactosidaseHomo sapiens (human)Potency3.98114.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency16.51770.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency13.44810.143427.612159.8106AID1159516
Bloom syndrome protein isoform 1Homo sapiens (human)Potency79.43280.540617.639296.1227AID2364; AID2528
cytochrome P450 2C9 precursorHomo sapiens (human)Potency6.58120.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency1.83560.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.58960.000323.4451159.6830AID743065
mitogen-activated protein kinase 1Homo sapiens (human)Potency35.48130.039816.784239.8107AID1454
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.79430.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency0.89130.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency22.87410.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency15.84890.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.12590.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency19.06660.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency31.62280.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency50.10620.001551.739315,848.9004AID1259244; AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency31.62280.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency31.62280.01418.602439.8107AID2572
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency6.58120.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)23.34500.00020.850210.0000AID625177
MyeloperoxidaseHomo sapiens (human)IC50 (µMol)2.10000.02001.88117.6800AID701373
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)53.10000.00032.177410.0000AID1253839; AID578495
Procathepsin LHomo sapiens (human)IC50 (µMol)1.92000.00021.66619.5100AID1253840
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)50.01150.00051.28547.6500AID597385; AID597386
AromataseHomo sapiens (human)IC50 (µMol)27.00000.00001.290410.0000AID280410
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)30.57330.00021.557410.0000AID161505; AID161665; AID161681; AID241401; AID597384; AID625243; AID711545
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)26.96980.00010.995010.0000AID1423035; AID160238; AID162638; AID162655; AID1727721; AID241402; AID546254; AID597385; AID625244; AID711544
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)1.16000.00101.453910.0000AID1253840; AID578496
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)14.88400.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki11.82600.00021.11158.0280AID625256
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (227)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
response to yeastMyeloperoxidaseHomo sapiens (human)
hypochlorous acid biosynthetic processMyeloperoxidaseHomo sapiens (human)
respiratory burst involved in defense responseMyeloperoxidaseHomo sapiens (human)
defense responseMyeloperoxidaseHomo sapiens (human)
response to oxidative stressMyeloperoxidaseHomo sapiens (human)
response to mechanical stimulusMyeloperoxidaseHomo sapiens (human)
removal of superoxide radicalsMyeloperoxidaseHomo sapiens (human)
response to foodMyeloperoxidaseHomo sapiens (human)
response to lipopolysaccharideMyeloperoxidaseHomo sapiens (human)
low-density lipoprotein particle remodelingMyeloperoxidaseHomo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
negative regulation of apoptotic processMyeloperoxidaseHomo sapiens (human)
defense response to fungusMyeloperoxidaseHomo sapiens (human)
response to gold nanoparticleMyeloperoxidaseHomo sapiens (human)
defense response to bacteriumMyeloperoxidaseHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (93)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
chromatin bindingMyeloperoxidaseHomo sapiens (human)
peroxidase activityMyeloperoxidaseHomo sapiens (human)
protein bindingMyeloperoxidaseHomo sapiens (human)
heparin bindingMyeloperoxidaseHomo sapiens (human)
heme bindingMyeloperoxidaseHomo sapiens (human)
metal ion bindingMyeloperoxidaseHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (67)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
extracellular regionMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
nucleusMyeloperoxidaseHomo sapiens (human)
nucleoplasmMyeloperoxidaseHomo sapiens (human)
lysosomeMyeloperoxidaseHomo sapiens (human)
secretory granuleMyeloperoxidaseHomo sapiens (human)
azurophil granule lumenMyeloperoxidaseHomo sapiens (human)
azurophil granuleMyeloperoxidaseHomo sapiens (human)
intracellular membrane-bounded organelleMyeloperoxidaseHomo sapiens (human)
extracellular exosomeMyeloperoxidaseHomo sapiens (human)
phagocytic vesicle lumenMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (311)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1727726Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 0.01 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1128739In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in triglyceride level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hrs2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID282434Antiinflammatory activity against carrageenan-induced oedema in Wistar rat paw at 3 mg/kg, ip after 3 hrs relative to control2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
AID1727724Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 1 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID1815486Inhibition of B0AT1 (unknown origin) by radiolabled uptake assay2021Bioorganic & medicinal chemistry letters, 12-01, Volume: 53Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B
AID185240Percent inhibition of pleural inflammation in carrageenan-induced rat model was determined by comparing with vehicle control group when tested on 8 rats at peroral dose of 100 umol/Kg1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID161681The inhibitory activity against Prostaglandin G/H synthase 1 measured as TXB2 production after blood coagulation using human Whole blood assay2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors.
AID162638Inhibition of human Prostaglandin G/H synthase 2 at 10 ug/mL expressed as the mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID368205Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema volume at 300 umol/kg, po administered 1 hrs prior to carrageenan challenge measured after 3 hrs2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates.
AID282436Antiinflammatory activity against carrageenan-induced oedema in Wistar rat paw at 30 mg/kg, ip after 3 hrs relative to control2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID471360Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as inhibition of exudate production in pleural cavity at 20 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID1128732Inhibition of bovine COX-1 assessed as PGF2-alpha formation using arachidonic acid as substrate at 20 uM by enzyme immunoassay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1253839Inhibition of ovine COX-1 using arachidonic acid after 5 mins by colorimetric method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1294598Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells at 5 uM after 17 to 20 hrs by enzyme immunoassay relative to control2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID391924Analgesic activity in Wistar albino rat mouse assessed as reaction time for tail withdrawal at 100 mg/kg, po after 60 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID391923Analgesic activity in Wistar albino rat mouse assessed as reaction time for tail withdrawal at 100 mg/kg, po after 30 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID1253853Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells 10 uM in the presence of 500 uM P-gp inhibitor verapamil2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID478486Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po measured after 120 mins of carrageenan challenge relative to control2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives.
AID193756The percentage growth of paw after injection of carrageneen at a dose of 30 mg/kg dose2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors.
AID578497Inhibition of potato 5-LOX assessed as hydroperoxides production by EIA2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
AID1460296Growth inhibition of human DU145 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID391925Analgesic activity in Wistar albino rat mouse assessed as reaction time for tail withdrawal at 100 mg/kg, po after 120 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID1253851Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 1 hr by LC-MS method in the presence of 500 uM P-gp inhibitor verapamil2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1727721Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate measured after 10 mins by fluorometric based multimode microplate reader
AID1461582Antiproliferative activity against human LNCAP cells assessed as cell proliferation at 30 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID1253850Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells 1 uM in the presence of 500 uM P-gp inhibitor verapamil2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1783173Inhibition of human recombinant COX-2 at 1 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition
AID1069515Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in number of leukocytes in pleural space at 20 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative t2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID486696Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, po administered 30 mins before carrageenan challenge measured after 120 mins relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory-antimicrobial agents.
AID500919Inhibition of Hsp70 expression in heterozygous transgenic zebrafish embryo at 40 uM by Western blot analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID597388Inhibition of LTA4 hydrolase in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB4 production after 0.5 hrs by ELISA2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
AID500921Inhibition of COX2-mediated decrease in gata1 expression in heat-stimulated heterozygous transgenic zebrafish embryo assessed as restoration of gata1 level at 40 uM by in-situ hybridization analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1140773Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced increase in paw edema at 10 mg/kg, po after 30 mins (Rvb = 30.1 %)2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Design, synthesis, docking and anti-inflammatory evaluation of novel series of benzofuran based prodrugs.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1069518Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in exudate volume at 20 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID478487Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po measured after 180 mins of carrageenan challenge relative to control2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives.
AID1253840Inhibition of ovine COX-2 using arachidonic acid after 5 mins by colorimetric method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID471116Inhibition of COX1 in human whole blood assessed as TXB2 production by enzyme immunoassay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID293970Antiinflammatory activity against AA-induced ear edema in Swiss mouse at 300 umol/kg, po after 1 hr2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID1727727Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 0.001 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID1309231Stability in Balb/cCrSlc mouse plasma assessed as parent compound remaining up to 120 mins by HPLC analysis2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Isomeric iodinated analogs of nimesulide: Synthesis, physicochemical characterization, cyclooxygenase-2 inhibitory activity, and transport across Caco-2 cells.
AID1423034Inhibition of COX1 in human platelet microsomes assessed as reduction in formation of oxidized TMPD at 500 uM using arachidonic acid as substrate preincubated for 3 to 5 mins followed by arachidonic acid addition measured for 25 secs by spectrophotometric2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Tuning the Dual Inhibition of Carbonic Anhydrase and Cyclooxygenase by Dihydrothiazole Benzensulfonamides.
AID1058566Inhibition of recombinant His-tagged PDE4B1 (unknown origin) expressed in insect Sf9 cells using cAMP as substrate at 30 uM preincubated for 15 mins followed by substrate addition measured after 1 hr by luminescence assay relative to control2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.
AID1069512Plasma concentration in Wistar rat lambda carrageenan-induced pleurisy model at 20 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs by SPE-HPLC analysis2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID1294597Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.
AID239780Percentage plasma protein binding towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID733349Inhibition of COX-2 (unknown origin)-mediated TMPD oxidation using PGG2 as substrate at 100 uM incubated 15 mins prior to substrate addition measured after 36 secs by spectrophotometric analysis2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID391926Analgesic activity in Wistar albino rat mouse assessed as reaction time for tail withdrawal at 100 mg/kg, po after 180 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID1727723Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 10 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID1461586Induction of apoptosis in human MCF7 cells assessed as reduction in viable cells at 30 uM after 24 hrs by propidium iodide staining based FACS analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID1253838Lipophilicity, LogP of the compound at pH 7.4 by reverse-phase HPLC2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1423035Inhibition of human COX2 expressed in baculovirus infected sf21 cells assessed as reduction in formation of oxidized TMPD using arachidonic acid as substrate preincubated for 3 to 5 mins followed by arachidonic acid addition measured for 25 secs by spectr2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Tuning the Dual Inhibition of Carbonic Anhydrase and Cyclooxygenase by Dihydrothiazole Benzensulfonamides.
AID293972Antihyperalgesic effect against formalin-induced pain in mouse at 100 umol/kg, po assessed as licking activity in inflammatory phase2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID182289Percent inhibition of edema in carrageenan-induced rat paw edema was determined by comparing with vehicle control group when tested on 5 rats at peroral dose of 100 umol/Kg1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole.
AID386821Analgesic activity in Wistar albino rat mouse assessed as increase in reaction time for tail withdrawal at 100 mg/kg, po after 180 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID500916Inhibition of heat-induced AML1-ETO protein expression in heterozygous transgenic zebrafish embryo at 0.5 uM by Western blot analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID282435Antiinflammatory activity against carrageenan-induced oedema in Wistar rat paw at 10 mg/kg, ip after 3 hrs relative to control2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
AID1461581Antiproliferative activity against NHDF assessed as cell proliferation at 30 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID368212Inhibition of COX2 in LPS-stimulated human whole blood assessed as TXB2 production by enzyme immunoassay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID500920Inhibition of Hsp70 expression in heterozygous transgenic zebrafish embryo at 0.5 uM by Western blot analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1253837Lipophilicity, LogD of the compound at pH 7.4 by HPLC C18 method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID733353Inhibition of COX-1 (unknown origin)-mediated TMPD oxidation using PGG2 as substrate at 100 uM incubated 15 mins prior to substrate addition measured after 36 secs by spectrophotometric analysis2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.
AID1128738In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in LDL-cholesterol level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hr2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID1727719Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 1000 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID1069513Plasma concentration in Wistar rat lambda carrageenan-induced pleurisy model at 10 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs by SPE-HPLC analysis2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID1069516Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in number of leukocytes in pleural space at 10 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative t2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID368210Antinociceptive activity against formalin-induced pain in mouse assessed as inhibition of paw licking response during inflammatory phase at 300 umol/kg, po measured 15 to 30 mins after formalin injection2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID597384Inhibition of purified COX1 assessed as formation of oxidized TMPD during reduction og PGG2 to PGH2 preincubated for 15 mins by chromogenic assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
AID280410Inhibition of aromatase in SK-BR-3 cells by tritiated water release assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
AID1461588Induction of apoptosis in human MCF7 cells assessed as reduction in viable cells at 30 uM after 24 hrs by propidium iodide staining-based microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID1253844Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 1 hr by LC-MS method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID293967Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat at 300 umol/kg, po after 3 hrs2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1253836n-octanol/water partition coefficient, log P of the compound at pH 7.4 by HPLC C18 method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1253847Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells 10 uM2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1727720Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 100 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID241402In vitro inhibition activity against cyclooxygenase 2 with the compound dissolved in DMSO2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
AID478479Analgesic activity in Swiss albino mouse assessed as protection against acetic acid-induced writhing at 50 mg/kg, po administered 1 hr prior to acetic acid challenge relative to control measured after 3 hrs2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives.
AID756800Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.
AID193755The percentage growth of paw after injection of carrageneen at a dose of 10 mg/kg dose2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1294599Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells at 5 uM after 17 to 20 hrs by enzyme immunoassay relative to control2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.
AID1128714Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID282433Selectivity ratio of IC50 for human COX1 to IC50 for human COX22004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
AID471118Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as inhibition of exudate production in pleural cavity at 5 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID500924Inhibition of COX2-mediated decrease in gata1 expression in heterozygous transgenic zebrafish embryo assessed as restoration of gata1 level at 40 uM by in-situ hybridization analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID471362Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as decrease in exudate volume in pleural cavity at 10 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID1708783Inhibition of COX2 in human U87 cells assessed as prostaglandin E2 levels at 10 uM using arachidonic acid as substrate incubated for 12 hrs by ELISA (Rvb = 33.03 +/- 6.03 pg/ml)2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Small-Molecule HSP27 Inhibitor Abolishes Androgen Receptors in Glioblastoma.
AID1069522Inhibition of COX-2 in human whole blood assessed as PGE2 level in plasma after 5 mins by enzyme immunoassay2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID1461584Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID578496Inhibition of ovine COX2 assessed as PGF2alpha level by EIA2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
AID1253849Apparent permeability across basolateral to apical side in human Caco2 cells at 1 uM after 2 hrs by LC-MS method in the presence of 500 uM P-gp inhibitor verapamil2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID160238The inhibitory activity against cyclooxygenase Prostaglandin G/H synthase 2 (COX-2) measured as PGE-2 production after blood coagulation using human Whole blood assay2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors.
AID1253852Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC-MS method in the presence of 500 uM P-gp inhibitor verapamil2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID478485Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po measured after 60 mins of carrageenan challenge relative to control2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID578498Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX22011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
AID687424Inhibition of carrageenan-induced PGE2 production in Swiss mouse at 5 mg/kg, po dosed 45 mins before carrageenan dosing measured 3 hrs post carrageenan challenge by ELISA2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Mechanisms involved in the antinociceptive effects of 7-hydroxycoumarin.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1309233Acid dissociation constant, pKa of compound at 20 ug/ml at pH 5.6 to 6.8 by micro-scale spectrophotometric method2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Isomeric iodinated analogs of nimesulide: Synthesis, physicochemical characterization, cyclooxygenase-2 inhibitory activity, and transport across Caco-2 cells.
AID678720Metabolic stability in human liver microsomes assessed as low signal/noise ratio (S/N of 1 to 10) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID711544Inhibition of COX22011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID1069517Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in number of leukocytes in pleural space at 5 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID403344Inhibition of COX2 at 0.1 mM2005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1128733Inhibition of human recombinant COX-2 assessed as PGF2-alpha formation using arachidonic acid as substrate at 20 uM by enzyme immunoassay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID386822Analgesic activity in Wistar albino rat mouse assessed as reaction time for tail withdrawal at 100 mg/kg, po after 300 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID293971Antihyperalgesic effect against formalin-induced pain in mouse at 100 umol/kg, po assessed as licking activity in neurogenic phase2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1069521Selectivity ratio of IC50 for COX-1 in human whole blood to IC50 for COX-2 in human whole blood2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID241401In vitro inhibition activity against cyclooxygenase 1 with the compound dissolved in DMSO2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID471115Selectivity ratio of IC50 for COX1 to IC50 for COX2 in human whole blood2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID1460293Growth inhibition of human A549 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID1253842Apparent permeability across apical to basolateral side in human Caco2 cells at 1 uM after 1 hr by LC-MS method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1294600Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 5 uM by MTT assay relative to control2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.
AID282431Inhibition of COX1 in human whole blood assessed as inhibition of calcium ionophore A-23187-stimulated platelet aggregation by measuring TXB2 production2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
AID1708792Dissociation constant, pKa of the compound2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Small-Molecule HSP27 Inhibitor Abolishes Androgen Receptors in Glioblastoma.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID486694Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, po administered 30 mins before carrageenan challenge measured after 90 mins relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory-antimicrobial agents.
AID1069519Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in exudate volume at 10 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID756774Inhibition of HSP27 (unknown origin) assessed as increase in DTT-induced insulin B chain aggregation at 10 uM incubated for 5 mins prior to DTT-treatment measured after 30 mins by spectrophotometric analysis relative to control2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1294596Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.
AID293968Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1461585Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID711584Dissociation constant, pKa of the compound2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID1460294Growth inhibition of human HepG2 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID1140774Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced increase in paw edema at 10 mg/kg, po after 90 mins (Rvb = 38.7 %)2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Design, synthesis, docking and anti-inflammatory evaluation of novel series of benzofuran based prodrugs.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID578495Inhibition of ovine COX1 assessed as PGF2alpha level by EIA2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
AID161505Inhibition of human Prostaglandin G/H synthase 1 at 10 ug/mL expressed as the mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1294601Cytotoxicity against PMA-treated human U937 cells assessed as cell viability at 5 uM by MTT assay relative to control2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.
AID1253846Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1253848Apparent permeability across apical to basolateral side in human Caco2 cells at 1 uM after 1 hr by LC-MS method in the presence of 500 uM P-gp inhibitor verapamil2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID1128712Antioxidant activity in rat liver microsome membrane assessed as inhibition of lipid peroxidation after 45 mins by TBARS-based spectrophotometric assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID471119Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as inhibition of exudate production in pleural cavity at 10 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID486692Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, po administered 30 mins before carrageenan challenge measured after 60 mins relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory-antimicrobial agents.
AID1069523Inhibition of COX-1 in human whole blood assessed as thromboxane B2 level in serum after 5 mins by enzyme immunoassay2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID1128737In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in total cholesterol level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID386823Analgesic activity in Wistar albino rat mouse assessed as increase in reaction time for tail withdrawal at 100 mg/kg, po after 300 mins by tail flick method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Synthesis and anti-inflammatory evaluation of methylene bridged benzofuranyl imidazo[2,1-b][1,3,4]thiadiazoles.
AID1253841Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for ovine COX-22015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID478484Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po measured after 30 mins of carrageenan challenge relative to control2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives.
AID1460297Inhibition of recombinant His-tagged PDE4B1 (unknown origin) expressed in baculovirus infected sf9 cells at 10 uM using cAMP as substrate preincubated for 15 mins followed by cAMP addition measured after 1 hr by PDE light HTS assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID438000Cytotoxicity against human LTEDaro cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
AID377720Inhibition of sheep COX2 at 50 uM2006Journal of natural products, Jul, Volume: 69, Issue:7
Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances.
AID1253843Apparent permeability across basolateral to apical side in human Caco2 cells at 1 uM after 2 hrs by LC-MS method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID701373Inhibition of recombinant human myeloperoxidase2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.
AID756775Inhibition of bovine brain tubulin polymerization at 100 uM after 20 mins by spectrophotometric analysis relative to control in presence of GTP2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1128731Inhibition of squalene synthase in rat liver microsomes assessed as decrease in conversion of [3H]FPP to squalene2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
AID403345Inhibition of COX1 at 0.01 mM2005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1460295Growth inhibition of human HeLa cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1636448Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 22.7 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID471117Inhibition of COX2 in LPS-stimulated human whole blood assessed as PGE2 production by enzyme immunoassay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID500915Inhibition of heat-induced AML1-ETO protein expression in heterozygous transgenic zebrafish embryo at 40 uM by Western blot analysis2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID486690Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, po administered 30 mins before carrageenan challenge measured after 30 mins relative to control2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory-antimicrobial agents.
AID471363Antiinflammatory activity against gamma carrageenan-induced pleurisy in Wistar rat assessed as decrease in exudate volume in pleural cavity at 20 mg/kg, ip administered 30 mins before gamma carrageenan challenge measured after 4 hrs2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.
AID229511Ratio of IC50 value against COX-1 to that of COX-2 in whole blood assay.2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors.
AID597385Inhibition of purified COX2 assessed as formation of oxidized TMPD during reduction og PGG2 to PGH2 preincubated for 15 mins by chromogenic assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
AID546254Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.
AID597386Inhibition of human LTA4 hydrolase activity assessed as LTB4 production after 15 mins by ELISA2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1069520Antiinflammatory activity in Wistar rat lambda carrageenan-induced pleurisy model assessed as decrease in exudate volume at 5 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs relative to control2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID1253845Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs days by LC-MS method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.
AID368211Inhibition of COX1 in human whole blood assessed as TXB2 production by enzyme immunoassay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID293969Antiinflammatory activity against TPA-induced ear edema in Swiss mouse at 300 umol/kg, po after 6 hrs2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
AID711545Inhibition of COX12011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID282432Inhibition of COX2 in human whole blood assessed as inhibition of LPS-stimulated PGE2 production2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.
AID243023Ratio of in vitro inhibition activity of cyclooxygenase 1 to that of cyclooxygenase 22005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
AID711543Antiinflammatory activity in rat assessed as inhibition of paw edema at 10 mg/kg2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1365599Anti inflammatory activity in Wistar rat assessed as carrageenan-induced paw edema at 10 mg/kg, po pretreated for 15 mins followed by carrageenan addition measured after 90 mins (Rvb = 38.7%)2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Recently reported biological activities of pyrazole compounds.
AID162655Inhibitory activity was evaluated against human Prostaglandin G/H synthase 2 was determined1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry.
AID1461583Antiproliferative activity against human MCF7 cells assessed as cell proliferation at 30 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID368213Selectivity ratio of IC50 for human COX1 to IC50 for human COX2 by whole blood assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates.
AID1636390Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 31.7 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID597387Inhibition of COX2 in human whole blood assessed as inhibition of LPS-induced PGE2 production after 24 hrs by ELISA2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
AID1460298Inhibition of human COX2 expressed in baculovirus infected sf9 microsomes at 10 uM using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition by TMPD oxidation based assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID1069514Plasma concentration in Wistar rat lambda carrageenan-induced pleurisy model at 5 mg/kg, ip pretreated for 30 mins followed by lambda carrageenan-challenge measured after 4 hrs by SPE-HPLC analysis2014European journal of medicinal chemistry, Mar-03, Volume: 74N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.
AID1727725Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 0.1 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
AID161665Inhibitory activity was evaluated against human Prostaglandin G/H synthase 1 was determined1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1346949Rat B0AT1 (Neutral amino acid transporter subfamily)2014Biochemical pharmacology, Jun-01, Volume: 89, Issue:3
Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modelling.
AID1345284Human COX-1 (Cyclooxygenase)2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
AID1345206Human COX-2 (Cyclooxygenase)2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,171)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (2.82)18.7374
1990's242 (20.67)18.2507
2000's567 (48.42)29.6817
2010's279 (23.83)24.3611
2020's50 (4.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.00 (24.57)
Research Supply Index7.30 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index182.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (100.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials200 (15.72%)5.53%
Reviews79 (6.21%)6.00%
Case Studies103 (8.10%)4.05%
Observational4 (0.31%)0.25%
Other886 (69.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Diclofenac Potassium Versus Nimesulide in the Treatment of Fever and Pain in Children Aged 3 to 7 Years With Community Acquired, Non-complicated, Upper Respiratory Tract Infection [NCT01257126]Phase 40 participants (Actual)Interventional2011-04-30Withdrawn
Randomized, Open-label, Controlled Trial to Assess the Clinical Efficacy and Safety of Meloxicam Suspension 0.25 mg/kg/Day Once a Day, Versus Diclofenac 1 mg/kg/Day Twice a Day or Nimesulide 4 mg/kg/Day Twice a Day, for Five Days in the Treatment of Patie [NCT02229747]Phase 4128 participants (Actual)Interventional2001-08-31Completed
Evaluation of the Efficacy of a New Low Level Laser Therapy (LLLT) Home Protocol in the Treatment of the Temporomandibular Joint Disorders Related Pain. A Randomized, Double Blind Placebo Controlled Clinical Trial [NCT03119324]90 participants (Actual)Interventional2015-09-30Completed
Observational Study of Effectiveness and Safety of Add-on Milgamma® and Milgamma® Compositum Step-Therapy in Routine Practice of Management of Adult Patients With Acute Non-Specific Low Back Pain Receiving Modern NSAIDs [NCT03892707]500 participants (Actual)Observational2018-12-15Completed
Evaluation of Clinical Efficacy and Safety of the Drug Nise (Nimesulide) in Complex Treatment of Patients With Osteoarthritis of the Knee and Hip Joints [NCT02922712]Phase 4202 participants (Actual)Interventional2011-03-31Completed
Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint. [NCT04609748]Phase 230 participants (Anticipated)Interventional2021-01-27Recruiting
Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing Nimesulide 100 mg(Eskaflam®, GlaxoSmithKline México, S.A. de C.V. vs. Mesulid®, Producto de Roche, S.A. de C.V.) in Fasti [NCT01745614]Phase 128 participants (Actual)Interventional2010-07-18Completed
A Randomized Phase II Prevention Trial in Subjects at High Risk for Hormone Non-responsive Breast Cancer [NCT01500577]Phase 2150 participants (Actual)Interventional2005-04-30Completed
Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients. [NCT01670552]Phase 3490 participants (Actual)Interventional2016-02-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03892707 (11) [back to overview]Change in Pain-related Disability After 10 Days of Treatment
NCT03892707 (11) [back to overview]Change of Pain Intensity After 10 Days of Treatment
NCT03892707 (11) [back to overview]Change of Pain Intensity Over Time
NCT03892707 (11) [back to overview]Number of Treatment Days With NSAIDs
NCT03892707 (11) [back to overview]Percentage of Patients With at Least One Pain Flare-up During the Study
NCT03892707 (11) [back to overview]Change of Pain Intensity After 5, 24 and 38 Days of Treatment
NCT03892707 (11) [back to overview]Patient Satisfaction With Treatment
NCT03892707 (11) [back to overview]Percentage of Patients With 30% Low Back Pain Relief After 5, 10, 24 and 38 Days of Treatment.
NCT03892707 (11) [back to overview]Percentage of Patients With at Least One Pain Flare-up Resulting in Consultancy With Physician, Resulting in Disruption of Daily Activity, and Resulting in NSAIDs Intake
NCT03892707 (11) [back to overview]Prescribed and Actual Number of Milgamma® Injections
NCT03892707 (11) [back to overview]Prescribed and Actual Number of Treatment Days With Milgamma® Compositum
[back to top]

Change of Pain Intensity After 10 Days of Treatment

Pain intensity was measured using 0-10 point Numeric Rating Scale (NRS). NRS is 11-step scale for assessment of pain intensity at the moment of patient's examination ranging from 0 (no pain) to 10 (worst pain imaginable). Pain intensity was measured at baseline and at 10 days after the start of treatment. (NCT03892707)
Timeframe: Baseline; Visit 3 (10 days after the start of treatment)

Interventionunits on a scale (Mean)
NSAIDs Group-5.1
NSAIDs+Milgamma+Milgamma Compositum Group-4.0

[back to top]

Change of Pain Intensity Over Time

Pain intensity was measured using 0-10 point Numeric Rating Scale (NRS). NRS is 11-step scale for assessment of pain intensity at the moment of patient's examination ranging from 0 (no pain) to 10 (worst pain imaginable). Pain intensity was measured at baseline, at 5, 10, 24 and 38 days after the start of treatment. A mixed model repeated measures was used to analyze change from baseline in pain intensity over time from Baseline to Visit 5 (38 days after the start of treatment) in each group. The model included a random effect for subject and fixed effect terms for treatment, visit, treatment-by-visit interaction, baseline pain intensity. An unstructured covariance structure was used to model the within-subject errors. P-value was calculated for the difference between treatment groups. (NCT03892707)
Timeframe: From Baseline to Visit 5 (38 days after the start of treatment)

Interventionunits on a scale (Least Squares Mean)
NSAIDs Group-5.1
NSAIDs+Milgamma+Milgamma Compositum Group-4.4

[back to top]

Number of Treatment Days With NSAIDs

Number of treatment days with NSAIDs was calculated using the data collected on the NSAIDs intake during the study irrespective of the specific drug used. Duration of each intake period was determined as Stop date - Start date +1 and, finally, all individual duration values were summed up. In case medication intake was ongoing at the End of Study Visit, stop date was imputed by the date of study completion. (NCT03892707)
Timeframe: From Baseline to Visit 9 (End of Study Visit, 94 days after the start of treatment)/ Early Discontinuation Visit

InterventionDays of treatment (Mean)
NSAIDs Group9.6
NSAIDs+Milgamma+Milgamma Compositum Group10.6

[back to top]

Percentage of Patients With at Least One Pain Flare-up During the Study

Episode of pain flare-up was defined as presence of at least 1 day with low back pain following a period without pain lasting at least 4 weeks. Therefore pain flare-ups were registered no earlier than 4 weeks after the start of treatment, i.e. starting from Visit 5 (38 days after the start of treatment). The occurrence of pain flare-up was determined by the investigator. (NCT03892707)
Timeframe: From Visit 5 (38 days after the start of treatment) to Visit 9 (End of Study Visit, 94 days after the start of treatment)

InterventionParticipants (Count of Participants)
NSAIDs Group35
NSAIDs+Milgamma+Milgamma Compositum Group10

[back to top]

Change of Pain Intensity After 5, 24 and 38 Days of Treatment

Pain intensity was measured using 0-10 point Numeric Rating Scale (NRS). NRS is 11-step scale for assessment of pain intensity at the moment of patient's examination ranging from 0 (no pain) to 10 (worst pain imaginable). Pain intensity was measured at baseline, at 5, 24 and 38 days after the start of treatment.Changes of pain intensity from baseline to Day 5, from baseline to Day 24 and from baseline to Day 38 after the start of treatment were calculated separately. (NCT03892707)
Timeframe: Baseline; Visit 2 (5 days after the start of treatment), Visit 4 (24 days after the start of treatment); Visit 5 (38 days after the start of treatment)

,
Interventionunits on a scale (Mean)
Change of pain intensity from baseline to Day 5 after the start of treatmentChange of pain intensity from baseline to Day 24 after the start of treatmentChange of pain intensity from baseline to Day 38 after the start of treatment
NSAIDs Group-3.1-6.1-6.3
NSAIDs+Milgamma+Milgamma Compositum Group-2.4-5.3-6.0

[back to top]

Patient Satisfaction With Treatment

Patient satisfaction with treatment was evaluated using a 5-point verbal rating scale (1= very dissatisfied, 2= dissatisfied, 3= neutral, 4= satisfied, 5= very satisfied) after 5, 10, 38 days and 3 months (94 days) since the start of treatment. (NCT03892707)
Timeframe: Visit 2 (5 days after the start of treatment); Visit 3 (10 days after the start of treatment); Visit 5 (38 days after the start of treatment) and Visit 9 (94 days after the start of treatment)

,
Interventionunits on a scale (Mean)
Visit 2 (5 days after the start of treatment)Visit 3 (10 days after the start of treatment)Visit 5 (38 days after the start of treatment)Visit 9 (94 days after the start of treatment)
NSAIDs Group3.84.24.54.6
NSAIDs+Milgamma+Milgamma Compositum Group3.84.14.54.7

[back to top]

Percentage of Patients With 30% Low Back Pain Relief After 5, 10, 24 and 38 Days of Treatment.

Pain intensity was measured using 0-10 point Numeric Rating Scale (NRS). NRS is 11-step scale for assessment of pain intensity at the moment of patient's examination ranging from 0 (no pain) to 10 (worst pain imaginable). Relief in pain intensity was defined as 100%*(pain intensity at baseline - pain intensity at Visit 2, 3, 4 or 5)/ pain intensity at baseline. Percentage of patients showing at least 30% low back pain relief at Visit 2 (5 days after the start of treatment), at Visit 3 (10 days after the start of treatment), at Visit 4 (24 days after the start of treatment) and at Visit 5 (38 days after the start of treatment) were calculated separately. (NCT03892707)
Timeframe: Visit 2 (5 days after the start of treatment); Visit 3 (10 days after the start of treatment); Visit 4 (24 days after the start of treatment) and Visit 5 (38 days after the start of treatment)

,
InterventionParticipants (Count of Participants)
Number and percentage of patients with 30% pain relief at Day 5 after the start of treatmentNumber and percentage of patients with 30% pain relief at Day 10 after the start of treatmentNumber and percentage of patients with 30% pain relief at Day 24 after the start of treatmentNumber and percentage of patients with 30% pain relief at Day 38 after the start of treatment
NSAIDs Group194235241244
NSAIDs+Milgamma+Milgamma Compositum Group140214240241

[back to top]

Percentage of Patients With at Least One Pain Flare-up Resulting in Consultancy With Physician, Resulting in Disruption of Daily Activity, and Resulting in NSAIDs Intake

"Episode of pain flare-up was defined as presence of at least 1 day with low back pain following a period without pain lasting at least 4 weeks. Therefore pain flare-ups were registered no earlier than 4 weeks after the start of treatment, i.e. starting from Visit 5 (38 days after the start of treatment). The occurrence of pain flare-up was determined by the investigator.~Percentages of patients with at least one pain flare-up resulting in consultancy with physician or professional management, resulting in disruption of daily activity, and resulting in NSAIDs intake were analyzed separately." (NCT03892707)
Timeframe: From Visit 5 (38 days after the start of treatment) to Visit 9 (End of Study Visit, 94 days after the start of treatment)

,
InterventionParticipants (Count of Participants)
Patients with at least one pain flare-up resulting in consultancy with physicianPatients with at least one pain flare-up resulting in disruption of daily activityPatients with at least one pain flare-up resulting in NSAIDs intake
NSAIDs Group42019
NSAIDs+Milgamma+Milgamma Compositum Group448

[back to top]

Prescribed and Actual Number of Milgamma® Injections

Prescribed number of Milgamma® injections was reported at Baseline visit. Actual number of injections was calculated by counting the number of injections administered and reported starting from Visit 2. If the treatment was interrupted, the days patient did not receive Milgamma® injections were not contribute to the total number of injections. (NCT03892707)
Timeframe: From Baseline to Visit 9 (End of Study Visit, 94 days after the start of treatment)/ Early Discontinuation Visit

Interventionnumber of injections (Mean)
Prescribed exposure of Milgamma® injectionsActual exposure of Milgamma® injections
NSAIDs+Milgamma+Milgamma Compositum Group9.39.3

[back to top]

Prescribed and Actual Number of Treatment Days With Milgamma® Compositum

Prescribed number of treatment days with Milgamma® compositum intake was reported at Baseline visit. Actual number of treatment days was calculated by summing up all the individual periods of treatment with Milgamma® compositum (in days) reported starting from Visit 2. If the treatment was interrupted, the days patient did not receive Milgamma® compositum were not contribute to the total number of treatment days with Milgamma® compositum intake. (NCT03892707)
Timeframe: From Baseline to Visit 9 (End of Study Visit, 94 days after the start of treatment)/ Early Discontinuation Visit

InterventionDays of treatment (Mean)
Prescribed exposure of Milgamma® compositumActual exposure of Milgamma® compositum
NSAIDs+Milgamma+Milgamma Compositum Group30.129.9

[back to top]